



Health Technology Assessment (HTA)

HTA Protocol

| | |
|--------------------|---|
| Title | Revascularisation versus optimal medical therapy (OMT) for the treatment of chronic coronary syndrome (CCS) |
| Author/Affiliation | Magdalena Moshi ¹ , Lucy Anastasi ¹ , Danielle Stringer ¹ , Ning Ma ¹ , Thomas Vreugdenburg ¹ ¹ Royal Australasian College of Surgeons |
| Technology | Percutaneous transluminal coronary intervention (coronary angioplasty) Coronary artery bypass grafting (CABG) Optimal medical therapy (OMT) |
| Date | 10 June 2022 |

Executive Summary

Patients with chronic coronary syndrome (CCS) may be treated with optimal medical therapy (OMT), percutaneous coronary intervention (PCI) with OMT, or coronary artery bypass grafting (CABG) with OMT. These interventions are publicly reimbursed in Switzerland, and their use is well established in patients with acute coronary syndrome (i.e. those experiencing myocardial infarction or unstable angina). However, the comparative safety and effectiveness of PCI with OMT and CABG with OMT compared to OMT alone in CCS patients is unclear. The Federal Office of Public Health has contracted an independent evaluation of PCI and CABG in the population of CCS patients.

A systematic review of five databases (PubMed [MEDLINE], EMBASE [Ovid], the Cochrane Library, the INAHTA database and Econlit) will be conducted to capture contemporary literature. Medications and surgical techniques for the treatment of CCS are rapidly evolving technologies. Therefore, only studies from the year 2010 onwards will be considered. Due to the highly patient-specific and complex nature of OMT, OMT will not be defined in the study inclusion criteria. Recent systematic reviews (SRs) and meta-analyses (MA) that answer the research questions will be considered. Randomised controlled trials (RCTs) will be included in the absence of, or to update, existing SRs and MAs. Adverse event data may be supplemented with non-RCT data. If appropriate, the primary data will undergo a longitudinal meta-analysis. In the absence of long-term data, a pairwise meta-analysis will be performed to demonstrate the comparative clinical effectiveness of the interventions in CCS patients. Subgrouping, sensitivity analyses, and meta-regression will be performed to investigate variables among the data.

A secondary systematic search will identify literature that addresses the economic research questions. An independent evaluation will be performed in the absence of existing economic studies relevant to Swiss practice. This approach, refined through the HTA process, will most likely be evaluated through a Markov cohort model with a cost-utility analysis. Current cost and utility data from Switzerland will serve as inputs for the model. A budget impact analysis will be performed.

Social, legal, ethical, and organisational issues will be addressed through non-systematic, targeted searches. Issues highlighted in studies within the clinical section will also be included. The findings will be summarised narratively.

Contents

| | | |
|-----|---|----|
| 1 | Policy question | 1 |
| 2 | Research question | 1 |
| 3 | Medical background | 2 |
| 3.1 | Pathophysiology, symptoms and prognosis | 2 |
| 3.2 | Diagnosis | 3 |
| 3.3 | Epidemiology and burden of disease..... | 4 |
| 3.4 | Treatment pathway | 5 |
| 4 | Technology description | 6 |
| 4.1 | Invasive interventions | 6 |
| 4.2 | Non-invasive treatment..... | 9 |
| 5 | Population, intervention, comparator and outcomes | 12 |
| 6 | HTA key questions | 16 |
| 6.1 | Additional questions..... | 16 |
| 7 | Methodology..... | 17 |
| 7.1 | Clinical evaluation | 17 |
| 7.2 | Economic evaluation..... | 24 |
| 7.3 | Legal, social, ethical, and organisational issues..... | 29 |
| | References | 30 |
| 8 | Appendices..... | 36 |
| 8.1 | Appendix A..... | 36 |

Tables

| | | |
|---------|--|----|
| Table 1 | PICO criteria..... | 12 |
| Table 2 | Study selection criteria..... | 18 |
| Table 3 | Summary of the proposed economic evaluation methodology..... | 28 |
| Table 4 | Search strategy – PubMed (MEDLINE)..... | 36 |
| Table 5 | Search strategy – INAHTA Database..... | 38 |
| Table 6 | Search strategy – International Clinical Trials Registry Platform..... | 39 |
| Table 7 | Search strategy – EconLit (EBSCO)..... | 39 |
| Table 8 | Grey literature sources..... | 40 |

Abbreviations and acronyms

| | |
|----------------|--|
| ACE inhibitors | Angiotensin-converting enzyme inhibitors |
| ACS | Acute coronary syndrome/symptoms |
| ARBs | Angiotensin receptor blockers |
| BMS | Bare-metal stent |
| CABG | Coronary artery bypass graft |
| CAD | Coronary artery disease |
| CCB | Calcium channel blockers |
| CCS | Chronic coronary syndrome |
| CHEERS | Consolidated Health Economic Evaluation Reporting Standards |
| CHF | Swiss Francs |
| CI | Confidence interval |
| CMR | Cardiac magnetic resonance imaging |
| COPD | Chronic obstructive pulmonary disease |
| CTA | Coronary computerised tomography angiography |
| CTO | Chronic coronary total occlusion |
| CUA | Cost-utility analysis |
| CVD | Cardiovascular disease |
| DALYs | Disability-Adjusted Life Years |
| DEB | Drug-eluting balloon |
| DES | Drug-eluting stent |
| DHP-CCB | Dihydropyridine calcium channel blockers |
| DRG | Diagnosis-related groups |
| ECG | Electrocardiogram |
| EKG | Echocardiogram |
| EQ-5D | European quality of life five dimension |
| ESC | European Society of Cardiology |
| GRADE | Grading of Recommendation, Assessment, Development and Evaluations |
| HRQoL | Health-related quality of life |
| HTA | Health Technology Assessment |
| ICA | Invasive coronary angiography |
| ICHOM | International Consortium for Health Outcomes Measurement |
| ICTRP | International clinical trials registry platforms |
| IMA | Internal mammary/thoracic artery |
| INAHTA | Internal Network of Agencies for Health Technology Assessments |
| LAD | Left anterior descending artery |
| LDL-C | Low-density lipoprotein cholesterol |
| LMCA | Left main coronary artery stenosis |
| LVEF | Left ventricular ejection fraction |
| MACE | Major adverse cardiac event |
| MacNew | Quality of life after myocardial infarction questionnaire |
| mg/dL | Milligrams per decilitre |
| MI | Myocardial infarction |
| mmol/L | Millimoles per litre |
| NRSI | Non-randomised study of interventions |
| OMT | Optimal medical therapy |
| PCI | Percutaneous coronary intervention |
| PCSK9 | Proprotein convertase subtilisin-kexin type 9 |

| | |
|-------|--|
| PICO | Population, intervention, comparator, outcome |
| PTCA | Percutaneous transluminal coronary angioplasty |
| QALY | Quality-adjusted life years |
| RCT | Randomised controlled trial |
| SD | Standard deviation |
| SF-36 | Short form-36 |
| SMD | Standardised mean differences |
| SoF | Summary of findings |
| VKA | Vitamin K antagonist |
| WHO | World Health Organization |

Objective of the HTA Protocol

Based on a preliminary screening of the literature, the objectives of the health technology assessment (HTA) protocol are to:

- formulate the research question
- define the population, intervention, comparator, outcomes (PICO)
- describe the methodology to conduct a systematic literature search, extract, analyse and synthesise the data, and present the result in an HTA report on the topic.

Key questions are defined, addressing the main HTA domains – efficacy/effectiveness/safety, costs/budget impact/cost-effectiveness, ethical/legal/social issues and organisational issues.

1 Policy question

Each HTA topic entails a policy and a research question. In health care, a **policy question** is a request to regulate a reimbursement policy and is aimed at securing financing of health technologies. Such a request, related to a particular health technology, typically addresses an existing controversy around a technology.

Patients with chronic coronary syndrome (CCS) may be treated with conservative methods, including optimal medical therapy (OMT) and risk factor modifications (e.g. lifestyle modifications, etc.), with or without invasive interventions.¹⁻³ Revascularisation is an invasive intervention in which patients undergo percutaneous coronary intervention (PCI) – also known as percutaneous transluminal coronary angioplasty – or coronary artery bypass grafting (CABG).¹ These interventions aim to improve quality of life and reduce mortality.

Revascularisation procedures have been performed for decades and are well established as standard practice in patients with acute coronary syndromes (ACS).⁴⁻⁶ However, controversies regarding their implementation in CCS patients remain.^{6,7} Regarding mortality in CCS patients, clinical trials have yet to demonstrate which is superior – invasive or conservative intervention.⁸⁻¹³

To evaluate the available evidence regarding efficacy, effectiveness, and safety of PCI with OMT and CABG with OMT compared to OMT alone, an HTA will be conducted. The proposed HTA will also involve an economic evaluation of the intervention and comparator. Additionally, ethical, legal, social and organisational issues are to be explored.

An HTA will be of considerable value in determining whether the costs and benefits of invasive coronary artery surgery (i.e. PCI and CABG) justify the coverage of these services by mandatory health insurance for patients with CCS.

2 Research question

To answer a policy question, research questions must be defined and answered first. The **research questions** are answered by inquiry into the HTA topic, which requires data collection and analysis. Research questions are specific and narrow. This HTA report addresses the following research questions:

1. What are the benefits and harms of PCI plus OMT and CABG plus OMT compared to OMT alone for the treatment of CCS?

2. What are the cost-effectiveness and budget impact associated with PCI plus OMT and CABG plus OMT compared to OMT alone for the treatment of CCS?
3. What are the ethical, legal, social, or organisational issues associated with PCI plus OMT or CABG plus OMT compared to OMT alone for the treatment of CCS?

3 Medical background

3.1 Pathophysiology, symptoms and prognosis

CCS is also referred to as stable coronary artery disease (CAD), coronary heart disease, ischaemic heart disease, and multivessel disease.¹⁴ The signs and symptoms of the disease include ischemia, angina, and atherosclerotic plaque accumulation in coronary arteries. To be classified as CCS and not another form of cardiovascular disease (CVD), the signs and symptoms have to be stable for an extended period of time (typically 12 months post-ACS) and can be controlled through pharmaceutical intervention or revascularisation procedures.^{1 15} In addition, advanced calcification that causes 100% occlusion of a coronary artery for over three months (chronic total occlusion [CTO]), is considered to be an exacerbation of CCS.¹⁶

The pathophysiology of CCS is defined by atherosclerosis of the coronary arteries of the heart.^{1 14 17} Plaque accumulation on the inner tissue of the coronary arteries is known as an atherosclerotic lesion.¹⁸ Atrial atherosclerotic lesions are at risk of plaque rupture, during which the coagulation cascade (thrombogenesis) is set in motion and leads to constriction or occlusion of the vascular lumen.¹⁹ This may lead to myocardial infarction and/or sudden cardiac death.^{18 19} Additionally, protruding plaque may reduce the diameter of the artery and restrict blood flow to the heart muscle (i.e. myocardial ischaemia). The extent of this artery narrowing, known as stenosis, is not necessarily dependant on the lesion size because the artery may be enlarged through remodelling processes.¹⁹ Stenoses less than 70% are unlikely to result in symptoms, even during stress testing.¹⁹ Heart failure, left ventricular remodelling, myocardial ischaemia or necrosis, and ischaemic cardiomyopathy result from restricted blood flow caused by arterial stenoses.¹⁹

Patients may experience CCS differently – some may present symptomatically, others asymptotically.²⁰ Symptomatic patients report signs and symptoms such as burning pain or pressure of the chest (angina pectoria), shortness of breath, nausea, faintness, restlessness, a sense of impending doom, or chest discomfort.^{1 14 17 20} The discomfort is most often reported as being in the chest, but may come from the epigastrium, the lower jaw or teeth, between the shoulder blades, or the arms, wrists, or fingers.^{1 21} These symptoms may be brought on or exacerbated by stress and exercise.¹

Patients with stable angina pectoris experience reversible symptoms that occur reliably and repetitively over months and years.²²

Risk factors for developing CCS include obesity, smoking, family history of heart disease, hypertension, chronic kidney disease, diabetes mellitus (type 1 and 2), and dyslipidaemia.^{1 3 14 17} Without risk factor modifications or treatment, patients with CCS are at high risk of ACS and death. The goals when treating CCS are to reduce cardiac morbidity, reduce risk of acute cardiac events, and improve quality of life through the management of symptoms. It is recommended that all patients are prescribed medication and adopt lifestyle modifications, with or without undergoing revascularisation.^{1 23}

3.2 Diagnosis

Diagnosing CCS is an extensive process that generally involves physical examination, family history, diagnostic testing and imaging.^{1 17} Diagnostic testing for CCS, and possible concurrent cardiac and/or pulmonary conditions, can be non-invasive or invasive. Invasive testing is generally only considered in situations where non-invasive testing produced inconclusive results, or in high-risk patients where the type of revascularisation (i.e. PCI or CABG) that needs to be undertaken can only be determined with detailed visualisation.¹ The types of invasive and non-invasive diagnostic testing recommended by the *European Society of Cardiology (ESC)* guidelines are detailed.¹

Non-invasive testing

- **Biochemical tests:** laboratory investigations are performed to identify cardiovascular risk factors (e.g. high cholesterol, diabetes mellitus [type 1 or 2], renal dysfunction, etc.), and disease prognosis. Common tests include haemoglobin A1c (HbA1c), lipid profile (e.g. total cholesterol, high density cholesterol, triglycerides, and low-density lipoprotein cholesterol [LDL-C]), troponin T or I (for myocardial injury), and glomerular filtration rate (GFR).¹⁷
- **Electrocardiogram (ECG) – resting or exercise:** records cardiac electrical activity.¹⁷ Resting ECGs are a standard test used on patients with unexplained angina, chest pain, and/or chest discomfort. Exercise ECGs are rarely used, but do provide valuable complementary information on exercise tolerance, blood pressure, event risk and arrhythmias.^{1 17}
- **Echocardiogram (EKG) – resting or stress:** details cardiac structure, function, and anatomy using sound waves.¹⁷ Resting EKGs are a clinical tool that aid in the identification of regional wall motion abnormalities (indication of CCS) and diastolic functions, and the exclusion of other causes of ischemia and/or angina. In addition, resting EKGs can also aid in the diagnosis of concurrent cardiac diseases (e.g. heart failure, valvular diseases, cardiomyopathies). Stress EKG can be used to detect MI through exercise or pharmacological induced wall motion abnormalities.^{1 17}

- **Cardiac magnetic resonance (CMR) imaging – resting or stress:** details cardiac anatomy and function, when EKGs are inconclusive.¹⁷ Resting CMR can evaluate both regional and global cardiac function. The imaging can also evaluate systolic cardiac function and cardiac anatomy. Late gadolinium enhancement of CMR supports the characterisation of myocardial tissues. This specialised technique reveals myocardial pathology such as scarring and fibrosis.
- **Chest X-ray:** uses minimal doses of ionising radiation to produce images of the chest cavity.²⁴ The tests do not provide information that is directly important to CCS diagnosis. The information provided is helpful detecting potential heart failure and/ or pulmonary conditions. The main use of chest X-rays is to exclude additional causes of atypical presentation of chest pain.¹
- **Coronary computerised tomography angiography (CTA):** uses ionising radiation (X-ray imaging) to visualise the heart and the lumen of surrounding arteries.²⁵ CTA provides detailed non-invasive anatomical visualisation that is able to detect obstructive stenoses.^{1 25}

Invasive testing

- **Invasive coronary angiography (ICA):** a catheterisation procedure that uses ionising radiation (rapid x-ray imaging) to visualise the heart and lumen of surrounding arteries ICA is generally only indicated for patients suspected of having CCS if non-invasive testing is inconclusive. In some circumstances, ICA may be indicated if a non-invasive testing indicates a patient has a high risk of a cardiac event and the type of revascularisation (i.e. PCI or CABG) needs to be determined.¹

3.3 Epidemiology and burden of disease

The term cardiovascular disease (CVD) represents a group of diseases that affect the heart and blood vessels (e.g. CCS, heart failure, etc.).²⁶⁻²⁸ CVD is a leading cause of death in Switzerland and globally.²⁶ ²⁷ In 2019, CVD was the number one cause of death in Switzerland, responsible for 29% of all deaths.²⁶ Ischaemic heart disease was the cause of death for 6,785 individuals in 2019. Mortality rates were reported as 54.4 men and 24.9 women per 100,000 inhabitants.²⁶ In 2015, there were 19,501 reported new cases of CCS in Swiss males, and 15,370 new cases in women.²⁹ Switzerland has one of the lowest rates of age-standardised disease adjusted life years (DALYs) lost in males due to stroke, ischaemic heart disease and other CVDs.²⁹ Furthermore, in 2018 a Swiss cohort of CCS patients reported a 0.2% mortality rate after PCI.³⁰

Statistics from the United States of America report that 38% of all deaths are attributable to CVD, and of these 47% were patients with CCS.³¹ In 2015, CCS accounted for approximately 14% of deaths in men and 12% in women in Europe;²⁹ European men with CCS lost more than 21 million DALYs (14%); European women lost around 14.5 million (11.3%) DALYs.²⁹

3.4 Treatment pathway

The treatment for CCS can depend on a variety of risk factors, including comorbidities (e.g. hypertension, diabetes mellitus (type 1 and 2), obesity, hyperlipidaemia, chronic kidney disease), diet, smoking status, exercise regimen, and if the patient is symptomatic or asymptomatic.^{1 20 23 32} In general, the first step in a treatment pathway is to determine if the patient is symptomatic or asymptomatic. If the symptoms are reducing the patient's quality of life and/or the disease state and progression places the patient at an increased risk of an acute event (e.g. myocardial infarction [MI], heart failure, cardiovascular death, etc.), then the patient is indicated for further testing and angiogram with subsequent revascularisation (PCI or CABG), if necessary. When the symptoms do not affect the patient's quality of life and/or disease state, and progression do not place the patient at an increased risk of an acute event, the patient will be indicated for OMT alone. If the patient is tolerating OMT and does not develop symptoms and/or the disease does not progress, the patient will continue with their CCS management under their treating physician. In contrast, if the patient is not tolerating OMT or the disease does progress, the patient will likely be indicated for invasive coronary intervention.

A patient's synergy between percutaneous coronary intervention with taxus and cardiac surgery II (SYNTAX II) score and/or additional diagnostic information (**Section 3.2**) may be used to determine if they are indicated for PCI or a CABG procedure.³³ This tool was developed with the SYNTAX II Trial, incorporating the anatomical presentation of the disease to determine complexity and risk of CCS.³³ After invasive surgery, patients are generally treated with OMT (if the patient can tolerate OMT). If the patient's symptoms have not been relieved and/or the disease continues to progress after surgical intervention, the patient can undergo a subsequent invasive coronary intervention (PCI or CABG). If the patient's symptoms have been relieved and/or the disease does not progress after undergoing an invasive coronary procedure, the patient will continue to have their CCS managed by their treating physician.

4 Technology description

Invasive and non-invasive treatments are available for the treatment of symptomatic CCS patients.¹ There are several modifications of each therapy to suit individual patient needs. The 2019 ESC guidelines highlight three primary goals of treatment in CCS:¹

- improve health-related quality of life (via reducing frequency and severity of angina pectoris and other somatic and psychological complaints)
- reduce CCS-related morbidity (non-fatal MI and heart failure)
- reduce cardiovascular-related mortality.

4.1 Invasive interventions

PCI and CABG are invasive interventions that aim to restore blood flow in areas of myocardial ischaemia.¹ Clinical characteristics – such as comorbidities (e.g. diabetes mellitus (type 1 and 2), chronic kidney disease, chronic obstructive pulmonary disease [COPD], obesity), left ventricular ejection fraction (LVEF), presence of multivessel disease, presence of main stem stenosis, and the SYNTAX II score – determine if a patient is indicated for PCI (also commonly known as angioplasty or percutaneous transluminal coronary angioplasty [PTCA]) or CABG.³⁴

Some patients may have to undergo subsequent invasive revascularisation procedures.^{35 36} Compared to PCI-naïve patients, patients that have had a prior PCI are at an increased risk of having to undergo CABG within 6 months.³⁶ Similarly, patients that underwent PCI within 6 months of their original PCI are twice as likely to have an additional PCI compared to naïve patients.³⁶ However, compared to naïve patients, patients that had a prior CABG are less likely to have to undergo an additional CABG procedure.³⁶

4.1.1 Percutaneous coronary intervention

PCI is a minimally invasive approach, in which stenoses are directly manipulated to restore patency of the vessels and blood flow to the affected myocardial area. This may be performed with the placement of a bare-metal stent (BMS), drug-eluting stent (DES), or via balloon angioplasty.³⁷⁻³⁹

The individual procedures are described as follows:

- **Balloon angioplasty:** A catheter device moves the deflated balloon through a leg or arm artery to the location of the stenosis. The balloon is inflated, thus dilating the artery and dissecting the plaque.^{37 39} Afterwards, the device is retracted and removed.^{37 39} Balloon angioplasty was first used to treat CCS in 1977.^{38 39} According to clinical experts, this procedure is rarely performed and is generally reserved for smaller vessels.

- **Drug-eluting balloon (DEB) angioplasty:** This procedure and technology is similar to a traditional balloon angioplasty (described above).^{40 41} However, in this procedure the balloons are used to deliver a homogenous coating of immediate release, high concentration, short-acting pharmaceuticals (i.e. antiproliferative agents) to the surface of lesions.^{40 42} DEBs are designed to compress the plaque while concurrently eluting pharmaceuticals that prevent restenosis of the artery.⁴⁰⁻⁴² Unlike DESs and BMSs, DEBs can be utilised in torturous (i.e. long complex, twisted) vessels, small vessels, and calcified vessels.⁴⁰
- **Bare-metal stent angioplasty:** Like balloon angioplasty, a catheter feeds a stent to the stenosis. The stent is placed and retained to mechanically sustain the opening of the artery and stabilise plaque.³⁷ This method may be most appropriate for patients with intolerances to the drugs associated with DES.⁴³ A BMS was first implanted into human coronary artery in 1986.³⁹ In 2018, 0.2% of stents implanted Switzerland were BMS.³⁰
- **Drug-eluting stent (DES) angioplasty:** DES are the most common stent choice in angioplasty.³⁰ These stents act similarly to BMS; however, they are also coated with medications to prevent restenosis through neointimal hyperplasia.³⁷ Three generations of DESs have been released and used since the first implantation of such a medical device in 1999.^{38 39} In 2018, 99% of the stent type implanted in Switzerland were DES.³⁰

Restenosis (growth of vascular smooth muscle tissue) is a common adverse event of concern to PCI.³⁹ The strut thickness of the stent is key in reducing restenosis.⁴⁴ DESs also chemically prevent restenosis, whereas the other two technologies offer drug-free treatment.³⁷⁻³⁹ DESs are coated with medications that inhibit cell proliferation and activate signal transduction pathways.^{38 39 43} The challenge of restenosis (and accompanying chronic inflammation) are decreased in DEBs compared to DESs, as no stent polymer or stent scaffolding are implanted into an arterial wall.^{41 42} After the delivery of the pharmaceutical and plaque compression by the balloon, the artery can retake its original shape with minimal disturbance and diminish the possibility of abnormal arterial flow.⁴²

4.1.2 Coronary artery bypass grafting

CABG is used to bypass stenoses using veins or artery conduits grafted from elsewhere in the body (e.g. legs and arms).^{45 46} The procedure generally involves the heart being accessed through the use of full sternotomy (dividing or 'cracking' the sternum).⁴⁷ Various techniques can be used to conduct a CABG procedure. These techniques include the use of a cardiopulmonary bypass machine or performing a minimally invasive surgery.^{47 48}

Types of grafts

The bypass graft may be a complete graft (artery or vein) or a partial graft (artery/vein mix). Conduits used as grafts are generally harvested from a saphenous vein, radial artery, or internal mammary/thoracic artery (IMA).^{14 45 46 49} Grafts from saphenous vein are often used because the conduits can easily be harvested from the patient's legs. The superiority of either graft will not be addressed in the HTA as it is beyond the scope of the research questions (**Section 2**).

Use of a cardiopulmonary bypass machine

CABG may be performed with or without the use of a cardiopulmonary bypass machine (i.e. 'on-pump' vs 'off-pump').^{47 50} The machine provides the option of a bloodless surgical field as it can artificially circulate oxygenated blood throughout the patient's body after the heart has been stopped (i.e. cardioplegic arrest).^{47 50} A patient's heart is not stopped during an off-pump CABG procedure.^{47 51} Instead, other stabilisation techniques are used and the necessary coronary anastomoses are performed on the patient's beating heart.^{47 50 51} Typically, a CABG procedure is performed on-pump unless it is deemed unsafe due to the individual clinical presentation (e.g. calcification of the aorta, which prevents aortic clamping).^{47 52 53} This is because cardiopulmonary bypass has been previously associated with an increased risk of post-surgical morbidity in patients with comorbidities (e.g. diabetes mellitus (type 1 and 2), chronic kidney disease, COPD, obesity).^{47 54} This was supported by clinical experts, as they stated that off-pump procedures are generally only performed on high-risk patients when it is too dangerous to place them on cardiovascular bypass.

Minimally invasive direct coronary artery bypass grafting

Minimally invasive CABG procedures (referred to as a minimally invasive direct coronary artery bypass grafting [MIDCAB]) are infrequently performed and are generally reserved for a subpopulation of CCS patients.^{48 54 55} Unlike a standard CABG, the procedure avoids a full sternotomy and the use of the cardiovascular bypass machine.^{54 55} The procedure is used to treat CCS patients that have complex lesions and/or stenosis (both single vessel and multivessel) in the left anterior descending artery (LAD), because treatment with PCI or standard CABG is deemed too risky.⁵⁵ Given that a MIDCAB procedure is usually performed on a high-risk patient, a cardiopulmonary bypass machine is not used.^{48 54 55} During the procedure, the LAD is accessed through 5–6 cm incision made in the fourth or fifth left intercostal space.⁵⁴ The graft for the procedure is harvested from the left IMA at the level of the first rib.⁵⁴ Then the anastomosis of the conduit grafted from the IMA to a stabilised LAD is performed on a beating heart.⁵⁴

55

4.2 Non-invasive treatment

4.2.1 Optimal medical therapy

OMT (also known as pharmacological management) is a systemic and conservative form of treatment for CCS.¹ The pharmaceuticals are used alongside invasive coronary surgery to treat CCS patients. Nonetheless, OMT can also be used as a standalone treatment.^{1 23} It is recommended that patients are monitored for 2–4 weeks after the commencement of OMT to review their response to the therapy.¹ There is no universally accepted treatment regimen of OMT for CCS patients, because the prescribed medical therapy is patient-specific and based on intolerances, contraindications, and comorbidities.^{1 23}⁵⁶ The 2019 ESC guidelines determine how OMT is prescribed to CCS patients in Switzerland. Therefore, OMT detailed in these guidelines is described below and will be used as the standard definition of OMT described in the PICO criteria (**Section 5**).¹

The ESC recommends a variety of drug class combinations for CCS patients to manage their symptoms, slow the disease progression, and/or prevent acute events.¹ These drug classes include antiplatelet therapy, anti-ischaemic/anti-anginal therapy, renin angiotensin system blockers, and lipid-lowering therapy.¹

The drug classes, individual drugs, and drug applications recommended by the ESC to treat CCS patients are detailed below:¹

- **Antiplatelet therapy:** prevents blood clot formation by stopping platelets from sticking together.
 - **Oral P2Y12 inhibitors:** prasugrel and ticagrelor act as antiplatelet therapy for patients who have experienced acute coronary events.
 - **Vitamin K antagonist (VKA):** inhibits vitamin K production in the liver, which decreases the availability of vitamin K to aid in coagulation.^{57 58} Common VKAs used in Switzerland include phenprocoumon and acenocoumarol. Warfarin is not available in Switzerland.⁵⁹
- **Anti-ischaemic/anti-anginal therapy:** relieves angina and ischaemic symptoms.
 - **Beta-blockers:** for angina relief and reducing morbidity and mortality from CCS. Beta-blockers are indicated in patients with left ventricular dysfunction, heart failure, or previous ST-elevation MI. Bisoprolol or metoprolol are preferred for the treatment of CCS patients.²
 - **Calcium channel blockers (CCB):** antianginal therapy for the relief of ischaemia or angina and to control heart rate. Amlodipine is the most common CCB used in Switzerland to treat CCS. On occasion verapamil and diltiazem are also used in Switzerland.^{1 2 60}
 - **Non-dihydropyridine (DHP)-CCB:** reduce heart rate due to the drug being more myocardially-selective. Popular non-DHP- CCBs include verapamil and diltiazem.^{61 62}
 - **Dihydropyridine (DHP)-CCB:** May be effective for the treatment of angina where symptoms are not resolved with beta-blockers or CCB. DHP-CCB reduces heart rate

being vascular selective. Therefore, it is a first-line therapy in patients presenting with low resting heart rate. Examples of DHP-CCB drugs include nifedipine and amlodipine.²

- **Nitrates:** Short acting nitrates (e.g. sublingual and spray nitro-glycerine) are available for the immediate relief of angina symptoms. Long-acting nitrates (e.g. nitro-glycerine, isosorbide) are prescribed as a second-line treatment when DHP-CCB do not provide symptom relief, are not well tolerated by patients, and/or are contraindicated.¹ Other nitrates used to treat CCS include ranolazine, nicorandil and ivabradine.
- **Renin angiotensin system blockers:** relax veins and arteries, which in turn lowers a patient's blood pressure and makes it easier for their heart to pump blood.
 - **Angiotensin-converting enzyme (ACE) inhibitors:** enzyme inhibitors used to relax veins in high-risk patients; primarily prescribed to individuals with concurrent hypertension, LVEF \leq 40%, diabetes mellitus (type 1 and 2), or chronic kidney disease.
 - **Angiotensin receptor blockers (ARBs):** For patients with an intolerance to ACE inhibitors, ARBs may be an appropriate substitute. The combination of ARBs and ACE inhibitors may lead to an increase of renal adverse events in hypertension patients, so is not recommended.
- **Lipid-lowering therapy:** reduce cholesterol.
 - **Statins:** blocks the enzyme that the liver uses to produce cholesterol. Common statins include, atorvastatin, rosuvastatin, simvastatin, pravastatin, fluvastatin, pitavastatin, and pravastatin.² The goal stipulated by the ESC guidelines is to reduce LDL-C by 50% from baseline. In patients who have experienced a second event within two years, a lower target may be set.¹
 - **Ezetimibe:** reduces the amount of cholesterol absorbed through a patient's diet.⁶³ The drug may be taken in combination for patients who are unable to reach their LDL-C goals.¹
 - **Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors:** PCSK9-inhibitors (i.e. evolocumab, alirocumab) are lipid-lowering drugs that can reduce LDL-C by binding to LDL receptors and causing the lysosomal degradation.⁶⁴ These drugs are generally prescribed to patients who do not meet LDL-C targets using statin and/ or ezetimibe.

Clinical experts have advised that OMT regimens differ before and after revascularisation. Patients who have undergone revascularisation are likely to be on dual antiplatelet therapy and are likely to require less antianginal medication. Conversely, patients treated with OMT alone may require more antianginal therapy and fewer antiplatelet drugs.

A small study in a Swiss CCS population (2008) found almost all patients with CCS were prescribed antiplatelet therapy (98.6%).⁶⁵ Statins (84%), beta-blockers (75%), calcium antagonists (34%), and nitrates (51%) were also commonly administered.⁶⁵

It is important that lifestyle changes are made alongside OMT. Lifestyle changes (e.g. weight management, healthy diet, smoking cessation, and regular physical activity) are also a vital part of CCS treatment.^{1 23} However, regardless of the importance of lifestyle modifications to a CCS patient's overall treatment regimen, they will not be considered in the HTA as it is beyond the scope of the research questions (**Section 2**).

5 Population, intervention, comparator and outcomes

Table 1 PICO criteria

| | |
|---------------------|--|
| Population | Adults diagnosed with symptomatic CCS ^a <i>Exclusion criteria: ACS-naïve patients with no symptoms of CCS, ACS patients, or patients that experienced MI or unstable angina in the past 12 months</i> |
| Intervention | Invasive procedure(s) plus OMT: 1) CABG + OMT 2) PCI + OMT, including: a. Angioplasty with 3 rd generation drug-eluting stent (DES)+ OMT b. Drug-eluting balloon (DEB) angioplasty + OMT <i>Exclusion criteria: CABG with concurrent PCI</i> |
| Comparator | Any OMT administered to reduce the risk of cardiac events and relieve symptoms (angina and ischaemia) ^b |
| Outcomes | Clinical outcomes <ul style="list-style-type: none"> • MACE – composite of: all-cause mortality, MI, revascularisation, hospitalisation or stroke • All-cause mortality • Health-related quality of Life (HRQoL) <ul style="list-style-type: none"> ○ General HRQoL measures (e.g. SF-36) ○ Cardiac-specific HRQoL (e.g. SAQ-7) • Hospitalisation (i.e. acute myocardial infarction [MI], stroke [incl. ischaemic, haemorrhagic], heart failure) ^c • Revascularisation • Total adverse events • Serious adverse events (including stroke) Health economic outcomes <ul style="list-style-type: none"> • Budget impact • Cost-effectiveness/cost-utility • Direct medical costs of the technology and associated services |

Abbreviations:

ACS: acute coronary syndrome; **CABG:** Coronary artery bypass graft; **CCS:** chronic coronary syndrome; **CTO:** chronic total occlusion; **MACE:** major adverse cardiac events; **MI:** myocardial infarction; **OMT:** optimal medical therapy; **PCI:** percutaneous coronary intervention; **SAQ-7:** Seattle Angina Questionnaire; **SF-36:** Short-Form 36.

Notes:

^a Signs and symptoms include: ischemia; angina; angina with concurrent shortness of breath; atherosclerotic plaque accumulation in coronary arteries; and/ or 100% occlusion of a coronary artery for a minimum of three months (chronic total occlusion [CTO]).^{1 15 16}

^b OMT regimens are patient-specific, and account for drug intolerances, comorbidities, and non-adherence issues. As OMT is administered in both trial arms, the specifics of the OMT are considered negligible; thus, any OMT regimen will be accepted. If details are available, these will be evaluated against the European guidelines on chronic coronary syndromes.¹ Excluding studies that are not applicable to the Swiss healthcare system (e.g. use of novel drugs or inappropriate drug combinations).

^c Eligible new hospital admission for patients with coronary heart disease will be limited to the International Consortium for Health Outcomes Measurement (ICHOM) definition.⁶⁶

5.1 Population

The population of interest includes patients with symptomatic CCS (including CTO). Patients have CCS when they are diagnosed with atherosclerotic coronary arteries without acute symptoms, and have not experienced an acute event in the past 12 months.¹ Acute events include, but are not limited to, MI and unstable angina.^{1 67} CCS patients that are considered at a high risk of having an acute event (e.g. those with comorbidities, multivessel disease or left main coronary artery disease) will be included. Similarly, patients that had previously undergone revascularisation procedures will be included. In addition, ACS-naïve patients (i.e. reduced oxygen supply to the heart) with no symptoms of CCS will be excluded, because they are generally not eligible for PCI or CABG in clinical practice. The reason for this ineligibility is that the patients tend to have poor outcomes after undergoing PCI or CABG.^{20 32} No limitations will be placed on how long a patient has been symptomatic.

5.2 Intervention

The intervention of interest is coronary artery revascularisation (CABG or PCI) with concurrent OMT. The PCI techniques will be limited to include angioplasty (including DEB only) with or without stenting (only third generation DES). Similarly, CABG will include procedures performed with and without a cardiopulmonary bypass machine (i.e. off-pump vs on-pump) as well as procedures that are 'open' and minimally invasive (i.e. MIDCAB and totally endoscopic coronary artery bypass [TECAB] surgery). No limitations will be placed on composition of the CABG graft (i.e. complete [arterial] graft or partial [arterial/vein] graft) or where the CABG graft was harvested from (e.g. mammary, saphenous, etc.). Studies that include CABG with concurrent PCI will be excluded.

5.3 Comparator

The relevant comparator is OMT; because OMT regimens are idiosyncratic, it is not possible to predetermine a clear definition.^{1 56} Given that OMT will be administered in both study arms – intervention and comparator – it is not essential that OMT is clearly defined in the included studies. However, a limitation will be placed on OMT to ensure that the treatment in the included studies is in line with the 2019 ESC recommendations.¹ This will ensure that the OMT is applicable to the Swiss healthcare context.

5.4 Clinical outcomes

The main aim of treating adult patients with CCS is to relieve angina symptoms, improve quality of life, and reduce mortality and cardiac morbidity (i.e. MI and low LVEF).^{1 20 68} Therefore, only clinically important effectiveness outcomes will be included in this HTA. Most of the clinically important outcomes have been defined according to the standardised outcome measurements for patients with CCS, as published by the International Consortium for Health Outcomes Measurement (ICHOM).⁶⁹

MACE is a composite endpoint that is routinely used to evaluate clinical outcomes of cardiovascular interventions.⁷⁰⁻⁷² However, there is no clear definition of MACE, because the composition and relatedness of the included outcomes differ between settings and study designs.⁷² These varying compositions often makes it difficult to compare MACE between studies.⁷² For the purposes of the HTA, MACE will only include all-cause mortality, MI, revascularisation, hospitalisation and stroke. Clinical experts have suggested these components are commonly used to defined MACE within the Swiss healthcare context.

All-cause mortality will reflect if invasive coronary artery surgery (CABG or PCI) with concurrent OMT can be fatal to patients with CCS. Disease-specific mortality (e.g. cardiovascular mortality) has not been included as an outcome because it provides less meaningful information than all-cause mortality in patients with CCS.¹

Health-related quality of life can provide patient-centred information on physical, social, emotional and mental health, to guide clinical practice.^{66 73} The tools used to quantify and gather patient-centred information can be disease-specific or generic.^{66 73} Examples of disease-specific HRQoL that measure cardiac-related symptoms (e.g. chest pain and shortness of breath) include, but are not limited to the Seattle Angina Questionnaire (SAQ-7) and the Quality of Life after Myocardial Infarction (MacNew) questionnaire.⁶⁶ Similarly, examples of tools that measure general HRQoL include the European quality of life five dimension (EQ-5D) and short form-36 (SF-36).⁷⁴ No limitations will be placed on the type of HRQoL tools included.

Hospitalisation is a common indicator of disease progression.⁶⁶ Hospitalisation can provide an objective measure of the severity of the disease impact on patients. Hospitalisation will be limited to MI, stroke (including haemorrhagic and ischaemic), and heart failure.⁶⁶

Subsequent coronary artery revascularisation can occur in CCS patients that have previously undergone invasive coronary artery surgery (CABG or PCI).⁶⁶

Adverse events are defined as temporary, non-life-threatening, unintended responses associated with a medical intervention (e.g. a surgical procedure or pharmaceutical).⁶⁹ An adverse event does not necessarily need to have a clear causal relationship with the medical intervention. Adverse events

generally include an increase in disease severity, and/or the development of new symptoms or signs (including new disease).⁶⁹

Serious adverse events are unfavourable experiences associated with a medical intervention may be life-threatening at the time of occurrence.⁶⁹ The incidents do not need to have a causal relationship with the medical intervention to be considered a serious adverse event.⁶⁹ For this HTA, serious adverse events may need to be subdivided into four categories: events caused by pharmaceuticals; acute surgical complications; major surgical complications (CABG only); and interventional cardiology complications (PCI only).^{66 69} The surgical complications will be defined and delineated according to the standardised outcome measurements for CCS detailed by ICHOM.⁶⁶ The International Council for Harmonisation definitions for serious adverse events will be used to define serious adverse events caused by pharmaceuticals.⁶⁹

6 HTA key questions

1. Are PCI plus OMT and CABG plus OMT efficacious, effective and safe compared to OMT alone for the treatment of CCS?
2. What are the costs associated with PCI plus OMT or CABG plus OMT for the treatment of CCS?
3. Are PCI plus OMT and CABG plus OMT cost-effective compared to OMT alone for the treatment of CCS?
4. What is the budget impact of PCI plus OMT or CABG plus OMT for the treatment of CCS?
5. Are there any ethical, legal, or social issues associated with PCI plus OMT or CABG plus OMT for the treatment of CCS?
6. Are there any organisational issues associated with PCI plus OMT or CABG plus OMT for the treatment of CCS?

6.1 Additional questions

1. Is the safety and effectiveness of PCI plus OMT and CABG plus OMT versus OMT alone in CCS affected by characteristics impacting patient risk? These populations include:
 - a) Comorbidities that classify CCS patients as high risk (i.e. cardiovascular comorbidities [incl. hypertension, valvular heart disease, heart transplantation], non-cardiovascular comorbidities [incl. cancer, diabetes mellitus (type 1 and 2), obesity, chronic kidney disease, elderly])
 - b) Sex/ gender
 - c) Refractory angina
 - d) Left main coronary artery (LMCA) stenosis > 50%
 - e) Left ventricular ejection fraction (LVEF \leq 40%)
2. Is the safety and effectiveness of PCI plus OMT and CABG plus OMT versus OMT alone in CCS affected by prior revascularisation (with either PCI or CABG)?

7 Methodology

7.1 Clinical evaluation

The proposed methods have been developed with reference to the *Cochrane Handbook for Systematic Reviews of Interventions (version 6.2)*,⁷⁵ and presented in accordance with the Preferred Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.⁷⁶

7.1.1 Databases and search strategy

Systematic literature searches will be conducted in five biomedical databases – PubMed (MEDLINE), Embase (Ovid), the Cochrane Library, the INAHTA database and EconLit. Preliminary search strings are presented in **Appendix A**. During the HTA phase of this project, the PubMed (MEDLINE) search strategy detailed in **Table 4** will be adapted to Embase (Ovid) and the Cochrane Library. Search filters to exclude non-human studies, and specific publication types (i.e. editorials, letters to the editor, news articles, and conference abstracts) will be utilised in all searches. The searches will be designed to capture English, French, German, and Italian publications. Grey literature searches will be limited to searching HTA and specialist cardiology websites (**Table 8** in **Appendix A**). The International Clinical Trials Registry Platform (ICTRP) will be searched to identify relevant unpublished and/or ongoing clinical trials. Preliminary search strategies for clinical trial registers are listed in **Table 6** in **Appendix A**.

Given the constant development in PCI, CABG and OMT, the searches will be limited to include studies published after 1 January 2010. This date was selected because this is around the time that the current era of PCI, CABG, and OMT started.^{38 39 45 48 53 77 78} This date range was endorsed by a Swiss clinical expert. Trials published before this date will include PCI, CABG, and OMT that are not representative of technology, techniques, and population that are currently used in contemporary clinical practice in Switzerland.

7.1.2 Study selection

All results from systematic literature searches will be imported into Rayyan (Rayyan Systems Inc, United States) for study selection.⁷⁹ Rayyan allows for blinded title and abstract screening of citations between independent reviewers, and resolution of study inclusion conflicts.⁷⁹ Screening will be performed to include studies that meet the pre-defined study selection criteria (**Table 2**). Only studies published in World Health Organization (WHO) Mortality Stratum A will be included.⁸⁰ This limitation will ensure that all included studies have a comparable disease burden and cause of death to Switzerland.⁸⁰ Exclusion criteria will be based on publication type (e.g. case notes, case reports, opinion pieces).

Table 2 Study selection criteria

| | Inclusion criteria | Exclusion criteria |
|----------------------------------|--|--|
| Population | Adults diagnosed with symptomatic CCS ^a | ACS-naïve patients with no symptoms of CCS, ACS patients, or patients that experienced MI or unstable angina in the past 12 months |
| Intervention | Invasive procedure(s) with OMT for the treatment of CCS: <ul style="list-style-type: none"> • CABG + OMT • PCT + OMT, including: <ul style="list-style-type: none"> ○ 3rd generation DES + OMT ○ DEB angioplasty + OMT | Balloon angioplasty BMS 1 st and 2 nd generation DES CABG with concurrent PCI |
| Comparator | Any OMT administered to reduce the risk of cardiac events and relieve symptoms (angina and ischaemia) ^b | Other interventions |
| Outcomes | <p>Clinical outcomes</p> <ul style="list-style-type: none"> • MACE – composite of: all-cause mortality, MI, revascularisation, hospitalisation or stroke • All-cause mortality • Health-related quality of Life (HRQoL) <ul style="list-style-type: none"> ○ General HRQoL measures (e.g. SF-36) ○ Cardiac-specific HRQoL (e.g. SAQ-7) • Hospitalisation (i.e. acute myocardial infarction [MI], stroke [incl. ischaemic, haemorrhagic], heart failure) ^c • Revascularisation • Total adverse events • Serious adverse events (including stroke) <p>Health economic outcomes</p> <ul style="list-style-type: none"> • Budget impact • Cost-effectiveness/cost-utility • Direct medical costs of the technology and associated services | Inadequate data (e.g. no measures of variance, incongruous data reported between figures and text, etc), incomplete reporting, unclear follow-up duration, any other outcomes |
| Design / publication type | <p>Clinical evidence</p> <ul style="list-style-type: none"> • Systematic reviews and meta-analyses • Randomised controlled trials • Non-randomised studies of interventions <p>Economic evidence</p> <ul style="list-style-type: none"> • Cost-effectiveness/utility analyses • Budget impact analysis • Cost analysis | <ul style="list-style-type: none"> • Single arm studies • Case reports • Conference abstracts • Letter to the editor • Expert opinion • Editorial • Narrative review articles |
| Language | English, German, Italian, French | All other languages |
| Country | WHO Mortality Stratum A countries: Andorra, Australia, Belgium, Brunei, Canada, Croatia, Cuba, Cyprus, Czech Republic [Czechia], Denmark, Finland, France, Germany, Greece, Iceland, Ireland, Israel, Italy, Japan, Luxembourg, Malta, Monaco, The Netherlands, New Zealand, Norway, Portugal, San Marino, Singapore, Slovenia, Spain, Sweden, Switzerland, United Kingdom [UK], and United States of America [USA] | Non-Stratum A countries |
| Date | Studies published on or after 1 st of January 2010 | Studies published on or before 31 st December 2009 |

Abbreviations:

ACS: acute coronary syndrome/symptoms; **CABG:** Coronary artery bypass graft; **CCS:** chronic coronary syndrome; **CTO:** chronic total occlusion; **DEB:** drug eluting balloon; **DES:** drug eluting stent; **MACE:** major adverse cardiac events; **MI:** myocardial infarction; **OMT:** optimal medical therapy; **PCI:** percutaneous coronary intervention; **SAQ-7: SF-36:** Short-Form 36; **WHO:** World Health Organization.

Notes:

^a Signs and symptoms include: ischemia; angina; angina with concurrent shortness of breath; atherosclerotic plaque accumulation in coronary arteries; and/ or 100% occlusion of a coronary artery for a minimum of three months (chronic total occlusion [CTO]).^{1 15 16}

^b OMT regimens are patient-specific, and account for drug intolerances, comorbidities, and non-adherence issues. As OMT is administered in both study arms, the specifics of the OMT are considered negligible; thus, any OMT regimen will be accepted. If details are available, these will be evaluated against the European guidelines on chronic coronary syndromes.¹ The aim is to avoid including studies that are not applicable to the Swiss healthcare system (e.g. use of novel drugs or inappropriate drug combinations).

^c Eligible new hospital admission for patients with coronary heart disease will be limited to the ICHOM definition.⁶⁶

The search results will be screened by title and abstract by two reviewers blindly. To ensure the selection criteria are interpreted consistently between reviewers, two individual screening samples ($k = 250$ and $k = 250$ citations) will be screened by both reviewers in duplicate to calculate inter-rater reliability. The first sample of citations ($k = 250$) will be a training sample only, while the second sample will be used to calculate inter-reliability (Fleiss Kappa).⁸¹ An inter-reliability score of 0.7 or higher (Kappa ≥ 0.7) indicates substantial agreement between the reviewers.^{82 83} Where the inclusion of a study is unclear, the full text will be reviewed. From the completion of title and abstract screening, the full-text publications will be reviewed by each reviewer independently. Conflicts regarding final study inclusion will be settled by a third reviewer. The inclusion and exclusion decisions will be detailed in a PRISMA flow chart.⁷⁶

Study design

Different types of study designs will be considered for inclusion. Contemporary systematic reviews and meta-analyses that meet the PICO criteria (**Table 1**) will be included to assess the clinical outcomes associated with PCI (with OMT) and CABG (with OMT) compared to OMT alone. RCT evidence will be included in the absence of, or to update, existing systematic reviews and meta-analyses. If there is limited evidence for adverse events associated with invasive coronary artery surgery (CABG or PCI) with concurrent OMT, non-randomised studies of interventions (NRSI) that meet the PICO criteria (**Table 1**) will also be included.

7.1.3 Data extraction

Data will be extracted (on study-arm-level) from included publications by a single reviewer using a standardised template, which will be adapted according to the design of the included studies. Data checking will be performed against the original publication by a second reviewer. Conflicts between will be resolved by consensus. If consensus cannot be reached, a third independent reviewer will be consulted. Data to be extracted include:

- **study information:** author, country, publication date, randomisation technique (RCT only), study identifier, enrolment dates, setting (e.g. secondary or tertiary hospital) number of centres, study design, follow-up duration, inclusion and exclusion criteria.
- **demographic information:** number of participants, age, sex, body mass index, definition of disease, prior acute events, prior revascularisation, comorbidities (diabetes mellitus [type 1 and

2], chronic kidney disease, hypertension), LDL-C goals, number of major vessels operated on, time since previous ACS.

- **intervention and comparator:** PCI (e.g. balloon only, type of stent, number of stents placed), CABG details (e.g. off-pump procedure, on-pump procedure, invasive or minimally invasive), OMT regimen (e.g. medications administered, medication variations).
- **outcomes of interest:** number of events, final or change-from-baseline scores with standard deviations in any HRQoL measure.
- **additional noteworthy factors:** possible effect modifiers (e.g. type of PCI), limitations or key differences of the study.

Where data is presented in a graphical format instead of numerically, the data will be estimated using WebPlotDigitizer.⁸⁴

7.1.4 Analysis of study quality

Different appraisal criteria will be implemented to assess the quality of the included evidence base. The appraisal of the quality of the included evidence will be performed by a single reviewer and checked by a second reviewer. Any differences between the two reviewers will be settled via consensus. In situations where consensus cannot be met, a third reviewer will be consulted.

The quality and risk of bias tools used to appraise the included studies was dependent on the study design. Systematic reviews will be evaluated against the AMSTAR-II appraisal criteria.⁸⁵ RCTs will be evaluated with the Cochrane Risk of Bias 2.0 (RoB 2.0) tool.⁸⁶ The Cochrane Risk of Bias in Non-randomised Studies of Interventions (ROBINS-I) tool will be applied to NRSI.⁸⁷

The Grading of Recommendation, Assessment, Development and Evaluations (GRADE) approach will be used to evaluate the quality of the evidence used to calculate the overall effect size for each of the seven prioritised outcomes.^{88 89} The five domains (imprecision, inconsistency, indirectness, risk of bias, and publication bias) of the GRADE framework will be scored ('high', 'moderate', 'low' and 'very low') according to a decision algorithm developed by Pollock et al.^{88 90, 88 90} The overall strength of the evidence (overall GRADE score) associated with the effect sizes for each outcome will be presented in summary of findings (SoF) tables generated in GRADEpro.^{89 91}

7.1.5 Data analysis of efficacy, effectiveness, and safety outcomes

Data synthesis

The method of data synthesis will depend on whether relevant systematic reviews and meta-analyses are available. *De novo* analysis will not be performed if existing systematic or meta-analyses meet the inclusion criteria. In such cases, the results from the existing studies will be reported for the relevant outcomes outlined in **Table 1**, and synthesised into a GRADE SoF table.

In the absence of existing systematic reviews and meta-analyses, a *de novo* analysis of primary studies will be conducted. The statistical method used to synthesise primary studies will depend on the amount of data available; where there are at least 10 studies reporting an outcome, mixed-effect pairwise meta-regression models that incorporate follow-up duration as a covariate will be used to analyse the data.⁹²⁻⁹⁴ This model type enables clinical outcomes to be reviewed over the complete follow-up period and not just at specific timepoints.^{92 93 95} This will enable the meta-analysis to compare the short-term benefits of a PCI and OMT or CABG and OMT against the long-term benefits of OMT. This type of model is also referred to as a 'longitudinal meta-analysis'.^{92 95}

If there are insufficient data points to perform mixed-effect meta-regression models, pairwise meta-analyses that use random-effects models will be used to compare PCI and OMT or CABG and OMT against OMT for both continuous and dichotomous outcomes reported by at least 2 studies. For the short-term benefits of PCI (and OMT) and CABG (and OMT) to be compared against the long-term benefits of OMT, five time points – of 30 days, 1 year, 5 years, 10 years and more than 10 years – will be used. The 30 days timepoint will be limited to reporting the point estimates for HRQoL, adverse events, and serious adverse events. These predetermined timepoints have been selected following input from clinical experts and ICHOM guidance.⁶⁶

Given that it is not possible to include the personalised nature of OMT into the planned meta-analyses techniques, it will be assumed that all OMT is equivalent between treatment groups, and across trials. For the purpose of the clinical evaluation, the equivalency will be extended to two scenarios. The first scenario includes OMT prescribed per before and after revascularisation; the second scenario includes, OMT prescribed alone, compared to OMT prescribed alongside concurrent revascularisation.

Random-effects models will be used to account for variation between the various combinations of surgical procedures (CABG, PCI [BMS, DES]) and medications (e.g. antiplatelet therapy and anti-anginals) in OMT.^{75 95} A random-effects model will be used to account for variations in the populations and interventions used across the included studies.^{75 95}

Only one continuous outcome is included in the PICO (HRQoL), which will be analysed as either a mean difference or standardised mean difference (SMD) with 95% confidence intervals (CI). SMDs will be used if there are differences in the measurement scales used to report HRQoL across individual studies. The SMDs will be interpreted following the recommendations detailed in the *Cochrane Handbook for Systematic Reviews of Interventions (version 6.2)*, whereby SMD of 0.2 represents a small effect, 0.5 a moderate effect, and 0.8 a large effect.⁷⁵ In addition, SMDs will be re-expressed as the most reported scale of HRQoL included in the analysis.⁷⁵

Dichotomous outcomes will be evaluated as risk ratios with 95% CIs. In a situation where NRSIs are included, adverse event data will be meta-analysed (if possible) and reported as risk ratios with 95%

CIs, noting that the risk of confounding in these study designs is high. If it is not possible to meta-analyse these study types, the results will be described narratively.

Assessment of heterogeneity

Heterogeneity and inconsistency (pairwise or mixed-effect meta-regression) will be assessed statistically. The statistical methods that will be used to measure heterogeneity in both continuous outcomes and dichotomous outcomes are the Tau² and I² statistics. The I² statistic will be interpreted in accordance with the *Cochrane Handbook for Systematic Reviews of Interventions* (0–40% is possibly not important; 30–60% is moderate; 50–90% is substantial; and 75–100% is considerable heterogeneity).⁷⁵ The significance of I² will depend on the strength of the evidence for heterogeneity (i.e. Tau² and Chi²) as well as direction and size of the measured effect.⁷⁵ In situations where considerable heterogeneity is evident, it will be explored with either a meta-regression or subgroup analysis.

The results will be illustrated using forest plots, which will provide a visual representation of the effect sizes and the corresponding uncertainties. The forest plots will illustrate the individual timepoints in each included study as well as the overall effect, once adjusted for follow-up time.

If there are too few data points to perform a mixed-effect meta-regression model, a pairwise meta-analyses will be conducted, and the outcomes will be presented in a forest plot that visualises the effect size and variance at the predetermined timepoints.

Subgroup and sensitivity analysis

A variety of techniques (i.e. subgrouping, meta-regression, sensitivity analyses) will be used to investigate possible effect modifiers (e.g. high-risk patients, risk of bias, etc.).

Subgrouping will be used to explore a subset of participants (e.g. high-risk patients) or study characteristics.⁷⁵ The subgroup analyses will use random effects models with an assumption of a normal distribution. A two-tailed Z-test will be used to determine if the difference between the two groups is statistically significant. The difference between subgroups will be considered statistically significant if there is less than 5% of difference occurring by chance alone (i.e. $p < 0.05$). Given that none of the subgroup analyses include two or more groups, a Q-test will not be performed. If there are only 10 trials in the subgroup analyses Tau² will be calculated using trials in both subgroups. However, if the subgroup analyses included more than 10 trials, a separate Tau² will be calculated for each individual subgroup.

Meta-regressions will be performed to review the impact of effect modifiers on the outcomes detailed in the PICO criteria (**Table 1**). Meta-regression will only be performed for outcomes with a minimum of 10 studies.⁷⁵ The meta-regressions will use random effects models with an assumption of a normal distribution. If the covariate in question is categorical (e.g. type of PCI), dummy values will be used to

ensure a meta-regression can be performed. The impact of the covariate (i.e. effect modifiers) on the effect size for each outcome will be reported as the slope of the meta-regression. For continuous outcomes the regression slope will be expressed as the unit of analysis (e.g. SMD). However, for dichotomous outcomes, the regression slope will be expressed as a log of RR ($\ln[RR]$). The impact of the covariate (i.e. effect modifiers) on the effect size will be tested for statistical significance using a two tailed Z-test. If there is less than 5% chance of the slope occurring randomly (i.e. $p < 0.05$), it will be considered statistically significant. Given that none of the meta-regression include two or more covariates, a Q-test will not be performed. The proportion of variance (between study heterogeneity) explained by the relationship between a covariate and its point estimate, will be determined using R^2 . Individual bubble-plots with a fitted meta-regression line will be used to illustrate the relationship between a covariate and its effect size, for each outcome.

Finally, sensitivity analyses will be used to investigate the impact that uncertainty and decisions made during the development of the review method had on the effect size of each outcome. The sensitivity analyses will follow parameters listed above. Possible sources of uncertainty include risk of bias and imputed SD.⁷⁵

The effect modifiers that will be explored a priori are listed below:¹

Subgroup

- Comorbidities that classify CCS patients as high risk (i.e. cardiovascular comorbidities [incl. hypertension, valvular heart disease, heart transplantation], non-cardiovascular comorbidities [incl. cancer, diabetes mellitus (type 1 and 2), obesity, chronic kidney disease, elderly – over 75])
- LMCA stenosis > 50%
- LVEF \leq 40%
- Refractory angina

Meta-regression

- Naïve revascularisation vs prior revascularisation with PCI
- Naïve revascularisation vs prior revascularisation with CABG
- Sex

Sensitivity analysis

- Imputed data (e.g. SD)
- Risk of bias due to missing outcomes
- Risk of bias due to publications bias
- Risk of bias due to selection bias

It is important to note that the effect modifiers investigated may change during the analysis phase of the full HTA.

Assessment of publication bias

The risk of publication bias will be assessed by using tests for funnel plot asymmetry.⁹⁶ The funnel plot tests will only be performed for outcomes with a minimum of 10 studies.⁷⁵ In addition, publication bias will be assessed through searching clinical trial registries to identify unpublished trials. The findings will be described narratively.

Imputation methods for dealing with missing values

Missing standard deviations (SDs) will be imputed from available means, sample sizes, standard errors and 95% confidence intervals (95% CIs) using formulas detailed in the *Cochrane Handbook for Systematic Reviews of Interventions (version 6.2)*.⁷⁵

If continuous values need to be combined, formulas detailed in the *Cochrane Handbook for Systematic Reviews of Interventions (version 6.2)* will be used.⁷⁵

If the required data are not available to calculate SDs, they will be imputed using the 'impute_SD' function in *R Studio (R version 3.0.1)* package 'metagear', following the imputation methods described by Braken et al. (1992).⁹⁷⁻¹⁰⁰

For studies that report outcomes graphically, WebPlotDigitizer will be used to convert graph points into numerical values.⁸⁴

7.2 Economic evaluation

To inform the methodology of the economic evaluation, the economic literature will be systematically reviewed: (1) to identify any existing Swiss economic evaluations addressing the research question, and (2) in the absence of such studies, to identify relevant literature to guide an independent economic evaluation.

7.2.1 Review of the economic literature

The systematic literature searches described in **Section 7.1.1** will be used to identify relevant cost, cost-effectiveness, and budget impact studies. Screening will be performed as outlined in **Section 7.1.2** to identify studies aligned with the PICO criteria (**Table 1**). Only studies performed in WHO Mortality Stratum A will be included,⁸⁰ in order to capture populations representative of Switzerland. During initial screening, cost analyses, economic evaluations and budget impact analyses will all be included to identify studies relevant to research questions 2, 3, and 4 (**Section 6**).

To inform the methodology used to address research question 3 (**Section 6**), full economic evaluations (studies that value both costs and benefits of different treatments) will be grouped and prioritised for

data extraction. Data pertaining to the following domains will be extracted: evaluation type, model used (if relevant), population considered, intervention and comparator, country, perspective, time horizon, effectiveness measure, key assumptions, and study findings. Included studies will also be assessed for applicability to the Swiss context and review question.

In the case Swiss-specific evidence is retrieved, critical appraisal using an appropriate checklist (e.g. the Drummond checklist; the Consolidated Health Economic Evaluation Reporting Standards [CHEERS] checklist; the Philips checklist for decision-analytic models)¹⁰¹⁻¹⁰³ will be undertaken to determine its usefulness for decision making. If available evidence is sufficient for decision makers, study results would be reported narratively.

In the absence of current economic studies that address the research question within the Swiss context, an independent economic evaluation is the preferred approach due to limitations of applying evaluation results from other healthcare settings. This evaluation would be guided by existing peer-reviewed literature in the field. Data extracted from the included studies would inform the evaluation methodology; however, critical appraisal of the included studies would not be undertaken because no conclusions would be drawn from the extracted data. Any assumptions borrowed from the existing literature would be critically assessed. Initial scoping suggests an independent evaluation will likely be required, although this will be confirmed following the systematic literature searches. Below, we outline key methodological considerations for an independent evaluation, should this be required.

7.2.2 Methodological considerations for an independent economic evaluation

The two interventions – PCI with OMT and CABG with OMT – will be individually assessed against OMT alone. Analyses of CABG with concurrent PCI stenting and CABG versus PCI stenting are out of scope for this HTA.

The analysis will most likely use a state transition model to demonstrate the transition of patients through the various health states associated with CCS; however, this will be confirmed during the HTA. The health states of interest include CCS, individual MACE outcomes, and death.

Results of the clinical evaluation will inform the clinical input parameters of the economic model. Where data are unavailable, these figures will be supplemented by data from peer-reviewed literature and databases.

Perspective

The analysis will be conducted from a Swiss healthcare payer perspective as this is the relevant perspective for the decision maker. Direct medical costs for services covered by Swiss mandatory health insurance will be included, irrespective of the actual payer (which may include health insurers, other social insurance, the government, or patients). Non-medical and indirect costs will not be included (e.g. travel costs, informal care or productivity losses).

Population

The economic model will reflect Swiss patients with symptomatic CCS. The population will include both intervention-naïve CCS patients (no prior interventions) and CCS patients with a history of PCI or CABG revascularisation. During the HTA, it will be assessed whether healthcare costs and/or clinical outcomes differ between patients with and without a prior intervention. If significant differences are identified, subgroup analysis would be considered.

Two separate patient cohorts will be defined for the two individual assessments of cost-effectiveness (PCI with OMT versus OMT alone; CABG with OMT versus OMT alone). Patient characteristics in the identified clinical studies will be compared to the Swiss context during the HTA.

As an example, the SWISS-II study is one source that may provide information on the demographics (age, sex, risk factors/comorbidities, and prior PCI) of patients with CCS in Swiss practice.^{104 105} In the case where Swiss specific data is unavailable, data from neighbouring countries (France, Germany, Austria, Italy) in peer-reviewed literature may also be considered.

Intervention and comparator

The interventions to be included are PCI with OMT and CABG with OMT. These interventions will be compared with OMT alone.

OMT is administered in both the intervention and comparator groups; however, OMT regimens differ slightly between patients on OMT alone and patients after revascularisation.¹ Patients on OMT alone have single antiplatelet therapy with higher antianginal medication load. Patients after revascularisation require less antianginal medication but will be prescribed dual antiplatelet therapy. Besides changes in antiplatelet and antianginal medications, OMT regimens are similar between groups.¹ Discussions with a clinical expert suggest patients will most likely be prescribed statins and aspirin for life. The complete cessation of antianginal therapy is rare, apart from a period immediately after CABG. In this population, there may be reuptake in symptomatic patients. It is important that the economic analysis can capture differences in OMT use between intervention and comparator groups for costing purposes.

Other specifics of OMT (e.g. drug intolerances; non-adherence issues) will likely be considered negligible (per the PICO criteria, **Table 1**). Nonetheless, the impact of such issues on the clinical

outcomes (e.g. revascularisation; adverse events) would be accounted for within the clinical input parameters.

The use of OMT in patients undergoing PCI, CABG, or OMT alone will be sourced from the included RCT evidence. The medication classes to be considered include aspirin, beta-blockers, ACE inhibitors, statins, CCBs, P2Y₁₂ inhibitors and nitrates. While every attempt to present a comprehensive view of OMT will be made, the estimation of the use of some medications may be limited by inconsistent reporting.¹⁰⁶ These medications may be excluded from the analysis entirely (i.e. across both intervention and comparator arms) if meaningful cost values cannot be estimated. OMT will be recognised at the drug class level; therefore, we will estimate a unit cost for each drug class. The applicability of OMT resource use within the included RCTs to Swiss practice will be explored during the HTA.

Outcome of the analysis

The proposed approach will most likely be a cost-utility analysis (CUA). Effectiveness will be expressed using the quality-adjusted life year (QALY). Health state utilities may be informed by the quality-of-life data captured in the clinical review or sourced from other peer-reviewed literature. If HRQoL outcome data were available from the clinical evaluation, this would be assessed for relevance to the economic evaluation. Where HRQoL was expressed using a non-preference-based instrument, the availability of a mapping algorithm to transform the data into utilities would be considered. We would also consider the time horizon over which HRQoL data is available, and whether the data would provide overall estimates of QALYs gained or inform utility values applied to health states of a model. Alternatively (or supplementarily), externally sourced utility weights may be required—these would be applied to time spent in different health states to estimate QALYs gained. Mortality outcomes may be derived from the clinical section of the report and general population data (i.e. Swiss life tables).

Costs (resource use and unit costs) will be estimated using a combination of sources, including peer-reviewed literature, clinical care guidelines, Swiss diagnosis-related group (DRG) costs, TARMED positions, and the Spezialitätenliste. Costs will be estimated for the following items: PCI and CABG procedures, the associated hospital stay, OMT, follow-up, and the management of any adverse events or clinical events included in the model (yet to be finalised), such as revascularisation, MI and stroke.

Incremental cost-effectiveness ratios will be expressed as the cost per QALY gained. One-way deterministic sensitivity analysis and probabilistic sensitivity analysis will be undertaken to explore the impact of uncertainty in input parameters on the economic results. The probability of cost-effectiveness will be expressed as a function of willingness to pay (WTP).

Summary

In the absence of existing contemporary economic modelling relevant to the research question from the perspective of the Swiss healthcare payer, an independent economic evaluation will be performed.

Existing published models reflecting a similar patient population would act as a foundation for the independent economic evaluation. Details contributing to the structure of the proposed evaluation are outlined in **Table 3**.

Table 3 Summary of the proposed economic evaluation methodology

| | |
|------------------------------------|--|
| Perspective | Swiss healthcare payer |
| Patient population | Adults diagnosed with symptomatic CCS |
| Intervention | CABG + OMT or PCI + OMT |
| Comparator | Any OMT administered with the objective to reduce risk of cardiac events and relieve symptoms (angina and ischaemia) |
| Type of economic evaluation | CUA |
| Time horizon | Lifetime |
| Sources of inputs | Published meta-analyses, RCTs, observational studies, Spezialitätenliste, Analyseliste, TARMED, Swiss DRGs, expert opinion |
| Costs | Direct medical costs of revascularisation and OMT (CHF) Direct medical costs of patient follow-up and their clinical outcomes (revascularisation, coronary angiography, non-invasive diagnostic testing, outpatient visits, hospitalisations, adverse events) |
| Effect measure | QALYs |
| Discount | 3% p.a. for both costs and QALYs |

Abbreviations:

CABG: coronary artery bypass graft; **CCS:** chronic coronary syndrome; **CHF:** Swiss francs, **CUA:** cost-utility analysis, **DRG:** diagnosis-related group; **OMT:** optimal medical therapy, **PCI:** percutaneous coronary intervention; **QALY:** Quality-adjusted life year; **RCT:** randomised controlled trial

Notes:

OMT is patient-specific and will be assessed at the drug class level in the economic evaluation.

7.2.3 Budgetary impact analysis

The budget impact analysis (BIA) will be performed from the perspective of the Swiss healthcare payer. The size of the target population – symptomatic Swiss patients with CCS utilising the intervention (revascularisation procedures) – will be estimated using the TARMED or the Swiss DRG databases, supplemented with additional sources. Revascularisation procedures may be billed using either TARMED tariffs (PCI: 17.1110 to 17.1190) or Swiss DRGs (CABG: F06A, F06B, F06C, F06D; PCI: F24A, F24B, F24C, F24D, F24E, F24F). These codes are applicable for indications other than CCS; therefore, further information will be needed to estimate the size of the target population. For example, data from all 36 Swiss interventional cardiology centres (2018) provides information on the uptake of percutaneous cardiac procedures (including PCI) in Switzerland and may be used to inform current usage of PCI in CCS.³⁰

The projected costs (CHF) to the Swiss healthcare payer for revascularisation procedures in patients with CCS over a 5-year period under current policy and practice conditions will be evaluated.

A BIA may be undertaken to examine the financial implications of policy change (e.g. limiting the indication for reimbursement). The decision whether to perform such an analysis will be made in conjunction with the clinical and economic findings. As OMT regimens are different for patients who do

or do not have revascularisation (see **Section 7.2.2**), a substitution of revascularisation procedures with OMT alone could impact the cost of OMT for patients making the switch. OMT costs for patients after revascularisation and on OMT alone would be included in the BIA, and would be informed by results of the economic evaluation. Analysis into the safety and effectiveness of the intervention for high-risk subgroups may guide decisions around providing limitations of the services.

7.3 Legal, social, ethical, and organisational issues

The systematic literature searches detailed in **Section 7.1.1** will be used to identify literature relevant to the legal, social, ethical, and organisational issues related to PCI, CABG and OMT in symptomatic patients with CCS. Additional, targeted, non-systematic keyword searches for literature that addresses these domains will be conducted (**Table 8** in **Appendix A**). Systematic reviews, literature reviews, RCTs, non-randomised studies, single-arm studies, ethnographic studies, phenomenological studies, narrative research and case studies will be considered for inclusion. The included literature will be ordered in tables that describe the study characteristics and key findings. The results will be synthesised narratively.

References

1. Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. *Eur Heart J* 2020;41(3):407-77.
2. Braun MM, Stevens WA, Barstow CH. Stable Coronary Artery Disease: Treatment. *Am Fam Physician* 2018;97(6):376-84.
3. Smith SC, Jr., Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association. *J Am Coll Cardiol* 2011;58(23):2432-46.
4. Bernhard M. Forty years of percutaneous coronary intervention. *Cardiovascular Medicine* 2018(11)
5. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). *Eur Heart J* 2018;39(2):119-77.
6. Chacko L, J PH, Rajkumar C, et al. Effects of Percutaneous Coronary Intervention on Death and Myocardial Infarction Stratified by Stable and Unstable Coronary Artery Disease: A Meta-Analysis of Randomized Controlled Trials. *Circ Cardiovasc Qual Outcomes* 2020;13(2):e006363.
7. Simoons ML, Windecker S. Controversies in cardiovascular medicine: Chronic stable coronary artery disease: drugs vs. revascularization. *Eur Heart J* 2010;31(5):530-41.
8. Pfisterer M, Trial of Invasive versus Medical therapy in Elderly patients I. Long-term outcome in elderly patients with chronic angina managed invasively versus by optimized medical therapy: four-year follow-up of the randomized Trial of Invasive versus Medical therapy in Elderly patients (TIME). *Circulation* 2004;110(10):1213-8.
9. Pfisterer M, Buser P, Osswald S, et al. Outcome of elderly patients with chronic symptomatic coronary artery disease with an invasive vs optimized medical treatment strategy: one-year results of the randomized TIME trial. *JAMA* 2003;289(9):1117-23.
10. Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. *N Engl J Med* 2007;356(15):1503-16.
11. Hueb W, Lopes N, Gersh BJ, et al. Ten-year follow-up survival of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. *Circulation* 2010;122(10):949-57.
12. Maron DJ, Hochman JS, Reynolds HR, et al. Initial Invasive or Conservative Strategy for Stable Coronary Disease. *N Engl J Med* 2020;382(15):1395-407.
13. Boden WE, Stone PH. To stent or not to stent? Treating angina after ISCHEMIA-why a conservative approach with optimal medical therapy is the preferred initial management strategy for chronic coronary syndromes: insights from the ISCHEMIA trial. *Eur Heart J* 2021;42(14):1394-400.
14. Cleveland Clinic Staff. Coronary Artery Disease Cleveland: Cleveland Clinic; 2021 [updated 21 June 2021. Available from: <https://my.clevelandclinic.org/health/diseases/16898-coronary-artery-disease> accessed 12 January 2022].
15. Ford TJ, Corcoran D, Berry C. Stable coronary syndromes: pathophysiology, diagnostic advances and therapeutic need. *Heart* 2018;104(4):284-92.
16. Zakkar M, George SJ, Ascione R. Should chronic total occlusion be treated with coronary artery bypass grafting? . *Circulation* 2016;133(18):1807-16.
17. Mayo Clinic Staff. Coronary artery disease Rochester: Mayo Foundation for Medical Education and Research; 2020 [updated 05 June 2020 Available from: <https://www.mayoclinic.org/diseases-conditions/coronary-artery-disease/symptoms-causes/syc-20350613> accessed 11 January 2022].

18. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. *N Engl J Med* 2005;352(16):1685-95.
19. Boudoulas KD, Triposciadis F, Geleris P, et al. Coronary Atherosclerosis: Pathophysiologic Basis for Diagnosis and Management. *Prog Cardiovasc Dis* 2016;58(6):676-92.
20. Koshy AN, Dinh DT, Fulcher J, et al. Long-term mortality in asymptomatic patients with stable ischemic heart disease undergoing percutaneous coronary intervention. *Am Heart J* 2022;244:77-85.
21. Cassar A, Holmes DR, Jr., Rihal CS, et al. Chronic coronary artery disease: diagnosis and management. *Mayo Clin Proc* 2009;84(12):1130-46.
22. Yeghiazarians Y, Braunstein JB, Askari A, et al. Unstable angina pectoris. *N Engl J Med* 2000;342(2):101-14.
23. Pfisterer ME, Zellweger MJ, Gersh BJ. Management of stable coronary artery disease. *Lancet* 2010;375(9716):763-72.
24. Mayo Clinic Staff. Chest X-rays: Mayo Foundation for Medical Education and Research (MFMER); 2022 [cited 2022 March 17]. Available from: <https://www.mayoclinic.org/tests-procedures/chest-x-rays/about/pac-20393494>].
25. Mayo Clinic Staff. CT coronary angiogram: Mayo Foundation for Medical Education and Research (MFMER); 2022 [Available from: <https://www.mayoclinic.org/tests-procedures/ct-coronary-angiogram/about/pac-20385117> accessed March 17 2022].
26. Federal Statistics Office (FSO). Death and its main causes in Switzerland 2018 Online: Federal Statistical Office; 2021 [Available from: <https://www.bfs.admin.ch/bfs/en/home/statistics/health/state-health/mortality-causes-death/specific.assetdetail.16644533.html> accessed 26 November 2021 2021].
27. World Health Organization (WHO). The top 10 causes of death 2020 [Available from: <https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death> accessed 26 November 2021 2021].
28. Everson-Rose SA, Lewis TT. Psychosocial factors and cardiovascular diseases. *Annu Rev Public Health* 2005;26:469-500.
29. Wilkins E, Wilson L, Wickramasinghe K, et al. European cardiovascular disease statistics 2017: European Heart Network, 2017.
30. Nestelberger T, Twerenbold R, Cook S, et al. Coronary and structural heart interventions in Switzerland 2018. *Swiss Med Wkly* 2020;150(1516):w20200.
31. Murray CJ, Kulkarni SC, Ezzati M. Understanding the coronary heart disease versus total cardiovascular mortality paradox: a method to enhance the comparability of cardiovascular death statistics in the United States. *Circulation* 2006;113(17):2071-81.
32. Zhang KY, Gai LY, Gai JJ, et al. Four-year clinical outcome in asymptomatic patients undergoing coronary computed tomography angiography. *Chin Med J (Engl)* 2013;126(9):1630-5.
33. Escaned J, Collet C, Ryan N, et al. Clinical outcomes of state-of-the-art percutaneous coronary revascularization in patients with de novo three vessel disease: 1-year results of the SYNTAX II study. *Eur Heart J* 2017;38(42):3124-34.
34. Neumann F-J, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. *European heart journal* 2019;40(2):87-165.
35. Mohamed MO, Shoaib A, Gogas B, et al. Trends of repeat revascularization choice in patients with prior coronary artery bypass surgery. *Catheterization and Cardiovascular Interventions* 2021;98(3):470-80.
36. Bourassa MG, Detre KM, Johnston JM, et al. Effect of prior revascularization on outcome following percutaneous coronary intervention; NHLBI Dynamic Registry. *Eur Heart J* 2002;23(19):1546-55.
37. Byrne RA, Sarafoff N, Kastrati A, et al. Drug-eluting stents in percutaneous coronary intervention: a benefit-risk assessment. *Drug Saf* 2009;32(9):749-70.

38. Canfield J, Totary-Jain H. 40 Years of Percutaneous Coronary Intervention: History and Future Directions. *J Pers Med* 2018;8(4)
39. Iqbal J, Gunn J, Serruys PW. Coronary stents: historical development, current status and future directions. *Br Med Bull* 2013;106:193-211.
40. Waksman R, Pakala R. Drug-eluting balloon: the comeback kid? *Circulation: Cardiovascular Interventions* 2009;2(4):352-58.
41. Kayssi A, Al-Atassi T, Oreopoulos G, et al. Drug-eluting balloon angioplasty versus uncoated balloon angioplasty for peripheral arterial disease of the lower limbs. *Cochrane Database of Systematic Reviews* 2016(8)
42. Seedial SM, Ghosh S, Saunders RS, et al. Local drug delivery to prevent restenosis. *Journal of vascular surgery* 2013;57(5):1403-14.
43. Luscher TF, Steffel J, Eberli FR, et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. *Circulation* 2007;115(8):1051-8.
44. Iantorno M, Lipinski MJ, Garcia-Garcia HM, et al. Meta-Analysis of the Impact of Strut Thickness on Outcomes in Patients With Drug-Eluting Stents in a Coronary Artery. *Am J Cardiol* 2018;122(10):1652-60.
45. Diodato M, Chedrawy EG. Coronary artery bypass graft surgery: the past, present, and future of myocardial revascularisation. *Surg Res Pract* 2014;2014:726158.
46. Frazier AA, Qureshi F, Read KM, et al. Coronary artery bypass grafts: assessment with multidetector CT in the early and late postoperative settings. *Radiographics* 2005;25(4):881-96.
47. Møller CH, Penninga L, Wetterslev J, et al. Off-pump versus on-pump coronary artery bypass grafting for ischaemic heart disease. *Cochrane Database Syst Rev* 2012(3):CD007224.
48. Melly L, Torregrossa G, Lee T, et al. Fifty years of coronary artery bypass grafting. *J Thorac Dis* 2018;10(3):1960-67.
49. Abu-Omar Y, Taggart DP. Coronary artery bypass surgery. *Medicine* 2014;42(9):527-31.
50. Sarkar M, Prabhu V. Basics of cardiopulmonary bypass. *Indian J Anaesth* 2017;61(9):760-67.
51. Connolly MW, Subramanian VA, Patel NU. Multivessel coronary artery bypass grafting without cardiopulmonary bypass. *Operative techniques in thoracic and cardiovascular surgery* 2000;5(3):166-75.
52. Stoney WS. Evolution of cardiopulmonary bypass. *Circulation* 2009;119(21):2844-53.
53. Ennker JC, Ennker IC. Coronary artery surgery: now and in the next decade. *HSR Proc Intensive Care Cardiovasc Anesth* 2012;4(4):217-23.
54. Garg S, Raja SG. Minimally invasive direct coronary artery bypass (MIDCAB) grafting. *AME Medical Journal* 2020;5
55. Cremer J, Schoettler J, Thiem A, et al. The MIDCAB approach in its various dimensions. *HSR Proc Intensive Care Cardiovasc Anesth* 2011;3(4):249-53.
56. Oxner A, Elbaz-Greener G, Qui F, et al. Variations in Use of Optimal Medical Therapy in Patients With Nonobstructive Coronary Artery Disease: A Population-Based Study. *J Am Heart Assoc* 2017;6(11):e007526.
57. Lamberts M, Gislason GH, Lip GY, et al. Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study. *Circulation* 2014;129(15):1577-85.
58. Zirikli A, Bode C. Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation. *J Thromb Thrombolysis* 2017;43(3):365-79.
59. Maeder MT, König T, Bogdanovic S, et al. Quality of vitamin K antagonist oral anticoagulation in 322 patients with atrial fibrillation—real-life data from a survey in Eastern Switzerland. *Swiss Medical Weekly* 2017(39)

60. Schäfer HH, Scheunert U. Costs of current antihypertensive therapy in Switzerland: an economic evaluation of 3,489 patients in primary care. *Swiss Medical Weekly* 2013;143(4344)
61. Opie L. Pharmacological differences between calcium antagonists. *European heart journal* 1997;18(suppl_A):71-79.
62. Frishman WH. Calcium channel blockers: differences between subclasses. *American journal of cardiovascular drugs* 2007;7(1):17-23.
63. Clader JW. The discovery of ezetimibe: a view from outside the receptor. *Journal of medicinal chemistry* 2004;47(1):1-9.
64. Bergeron N, Phan BA, Ding Y, et al. Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk. *Circulation* 2015;132(17):1648-66.
65. Cook S, Stauffer J-C, Hess OM, et al. Current outpatient therapy of stable coronary artery disease in Switzerland. *Cardiovascular risk factors* 2010;283(157):126.
66. McNamara RL, Spatz ES, Kelley TA, et al. Standardized Outcome Measurement for Patients With Coronary Artery Disease: Consensus From the International Consortium for Health Outcomes Measurement (ICHOM). *J Am Heart Assoc* 2015;4(5)
67. Werdan K. Nationale Versorgungsleitlinie (NVL) Chronische KHK. *Cme* 2016;13(11):50-68.
68. Bakhai A, Hill RA, Dunder Y, et al. Percutaneous transluminal coronary angioplasty with stents versus coronary artery bypass grafting for people with stable angina or acute coronary syndromes. *Cochrane Database Syst Rev* 2005;2005(1):CD004588.
69. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Clinical safety data management: Definition and standards for expedited reporting E2A, 1994.
70. Poudel I, Tejpal C, Rashid H, et al. Major Adverse Cardiovascular Events: An Inevitable Outcome of ST-elevation myocardial infarction? A Literature Review. *Cureus* 2019;11(7):e5280.
71. Bosco E, Hsueh L, McConeghy KW, et al. Major adverse cardiovascular event definitions used in observational analysis of administrative databases: a systematic review. *BMC Med Res Methodol* 2021;21(1):241.
72. Kip KE, Hollabaugh K, Marroquin OC, et al. The problem with composite end points in cardiovascular studies: the story of major adverse cardiac events and percutaneous coronary intervention. *J Am Coll Cardiol* 2008;51(7):701-7.
73. Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. *Ann Intern Med* 1993;118(8):622-9.
74. Ware JE, Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. *Med Care* 1992;30(6):473-83.
75. Higgins J, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021): Cochrane; 2021 [Available from: www.training.cochrane.org/handbook].
76. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS medicine* 2009;6(7):e1000097.
77. Endo A. A historical perspective on the discovery of statins. *Proc Jpn Acad Ser B Phys Biol Sci* 2010;86(5):484-93.
78. Sergeant P. The future of coronary bypass surgery. *Eur J Cardiothorac Surg* 2004;26 Suppl 1:S4-6; discussion S6-7.
79. Ouzzani M, Hammady H, Fedorowicz Z, et al. Rayyan-a web and mobile app for systematic reviews. *Syst Rev* 2016;5(1):210.
80. World Health Organization. The world health report: shaping the future. List of member states by WHO region and mortality stratum. Geneva: World Health Organization, 2003:182-84.
81. Fleiss JL. Measuring nominal scale agreement among many raters. *Psychological bulletin* 1971;76(5):378.

82. Landis JR, Koch GG. The measurement of observer agreement for categorical data. *Biometrics* 1977;33(1):159-74.
83. Nichols TR, Wisner PM, Cripe G, et al. Putting the kappa statistic to use. *The Quality Assurance Journal* 2010;13(3-4):57-61.
84. Rohatgi A. WebPlotDigitizer (version 4.5) Pacifica: Ankit Rohatgi; 2021 [Available from: <https://automeris.io/WebPlotDigitizer> accessed 6 Jan 2022].
85. Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. *BMJ* 2017;358:j4008.
86. Sterne JAC, Savovic J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ* 2019;366:l4898.
87. Sterne JA, Hernan MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. *BMJ* 2016;355:i4919.
88. Schünemann H, Brożek J, Guyatt G, et al. GRADE handbook for grading quality of evidence and strength of recommendations: The GRADE Working Group, 2013.
89. Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. *J Clin Epidemiol* 2011;64(4):383-94.
90. Pollock A, Farmer SE, Brady MC, et al. An algorithm was developed to assign GRADE levels of evidence to comparisons within systematic reviews. *J Clin Epidemiol* 2016;70:106-10.
91. GRADEpro GDT. GRADEpro Guideline Development Tool (Software): McMaster University and Evidence Prime; 2021 [Available from: grade.pro.org accessed 6 Jan 2022].
92. Ishak KJ, Platt RW, Joseph L, et al. Meta-analysis of longitudinal studies. *Clin Trials* 2007;4(5):525-39.
93. Musekiwa A, Manda SO, Mwambi HG, et al. Meta-analysis of effect sizes reported at multiple time points using general linear mixed model. *PloS one* 2016;11(10):e0164898.
94. Rubio-Aparicio M, López-López JA, Viechtbauer W, et al. Testing categorical moderators in mixed-effects meta-analysis in the presence of heteroscedasticity. *The Journal of Experimental Education* 2020;88(2):288-310.
95. Maas CJ, Hox JJ, Lensvelt-Mulders GJ. Longitudinal meta-analysis. *Quality and Quantity* 2004;38(4):381-89.
96. Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. *Biometrics* 2000;56(2):455-63.
97. Bracken M. Statistical methods for analysis of effects of treatment in overviews of randomized trials. *Effective care of the newborn infant* 1992:13-20.
98. Lajeunesse MJ. Comprehensive Research Synthesis Tools for Systematic Reviews and Meta-Analysis (version 0.7). Package 'metagear', 2021.
99. R Core Team. R: A language and environment for statistical computing. Vienna: Foundation for Statistical Computing, 2021.
100. R Studio Team. RStudio: Integrated Development for R. RStudio: Boston, 2021.
101. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. *BMJ (Clinical research ed)* 1996;313(7052):275-83.
102. Philips Z, Ginnelly L, Sculpher M, et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. *Health Technol Assess* 2004;8(36):iii-iv, ix-xi, 1-158.
103. Husereau D, Drummond M, Augustovski F, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. *Value Health* 2022;25(1):3-9.

104. Erne P, Schoenenberger AW, Burckhardt D, et al. Effects of percutaneous coronary interventions in silent ischemia after myocardial infarction: the SWISSI II randomized controlled trial. *JAMA* 2007;297(18):1985-91.
105. Schoenenberger AW, Jamshidi P, Kobza R, et al. Progression of coronary artery disease during long-term follow-up of the Swiss Interventional Study on Silent Ischemia Type II (SWISSI II). *Clin Cardiol* 2010;33(5):289-95.
106. Wijesundera HC, Mitsakakis N, Witteman W, et al. Achieving quality indicator benchmarks and potential impact on coronary heart disease mortality. *Can J Cardiol* 2011;27(6):756-62.

8 Appendices

8.1 Appendix A

Table 4 Search strategy – PubMed (MEDLINE)

| Group | Query | |
|--------------|-------|---|
| Population | 1 | Coronary[tiab] |
| | 2 | CAD[tiab] |
| | 3 | (1 OR 2) AND (obstruction[tiab] OR occlusion[tiab] OR occluded[tiab] OR stenosis[tiab] OR stenoses[tiab] OR lesion[tiab] OR "syndrome X"[tiab] OR microvascular disease*[tiab]) |
| | 4 | "Coronary artery disease"*[tw] |
| | 5 | "Stable coronary disease"*[tiab] |
| | 6 | "tandem lesion"*[tiab] OR "bifurcation lesion"*[tiab] OR "atherosclerotic lesion"*[tiab] OR "coronary artery lesion"*[tiab] |
| | 7 | "Single vessel disease"[tiab] |
| | 8 | "Multivessel disease"[tiab] |
| | 9 | "Stable coronary artery disease"*[tiab] |
| | 10 | "Stable ischemic heart disease"*[tiab] |
| | 11 | "Chronic ischemic heart disease"*[tw] |
| | 12 | "Coronary heart disease"*[tw] |
| | 13 | "Atherosclerotic heart disease"*[tiab] |
| | 14 | "Nonobstructive coronary artery disease"*[tiab] |
| | 15 | "Obstructive coronary artery disease"*[tiab] |
| | 16 | Atherosclero*[tw] |
| | 17 | "Cardiovascular disease"*[tw] |
| | 18 | "chronic coronary syndrome"*[tiab] |
| | 19 | "stable angina"[tw] |
| | 20 | "after myocardial infarction"*[tiab] |
| | 21 | after[tiab] AND "anterior myocardial infarction"*[tiab] |
| | 22 | after[tiab] AND "posterior myocardial infarction"*[tiab] |
| | 23 | "Myocardial ischemia"*[tiab] |
| | 24 | "myocardial ischaemia"*[tiab] |
| | 25 | "Stable ischaemic heart disease"*[tiab] |
| | 26 | 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14 OR 15 OR 16 OR 17 OR 18 OR 19 OR 20 OR 21 OR 22 OR 23 OR 24 OR 25 |
| Intervention | 27 | PTCA[tiab] |
| | 28 | CABG[tiab] |
| | 29 | PCI[tiab] |
| | 30 | "Coronary intervention"*[tw] |
| | 31 | "Percutaneous coronary intervention"*[tw] |
| | 32 | "Percutaneous transluminal coronary angioplasty"[tiab] |
| | 33 | "Percutaneous coronary angioplasty"[tiab] |
| | 34 | Angioplast*[tw] |
| | 35 | "Multivessel angioplasty"*[tiab] |

| Group | Query |
|-------------------|--|
| | 36 "Artery angioplasty*"[tiab] |
| | 37 "coronary angioplasty*"[tiab] |
| | 38 Balloon angioplasty*"[tiab] |
| | 39 "Myocardial revascularisation*"[tw] |
| | 40 "Myocardial revascularisation*"[tw] |
| | 41 "Artery bypass grafting*"[tw] |
| | 42 "Coronary artery bypass*"[tw] |
| | 43 "Coronary artery bypass graft*"[tw] |
| | 44 Angiograph*[tw] |
| | 45 Coronary[TW] AND (START[ti] OR TOSCA[ti] OR RAVEL[ti] OR WIDEST[ti] OR ELUTES[ti] OR APPLAUSE[ti] OR TAXUS [ti] OR SIRIUS[ti] OR SCANDSTENT[ti] OR DELIVER[ti] OR SWISSI[ti] OR RITA[ti] OR GISSOC[ti] OR DESTINI[ti] OR SISCA[ti] OR LASMAL[ti] OR OCBAS[ti] OR C-SIRIUS[ti] OR ESIRIUS[ti] OR GISSOC[ti] OR PRISON[ti] OR BENESTENT[ti] OR DEBATE[ti] OR TOAT[ti] OR STOP[ti] OR ADVANCE[ti] OR SARECCO[ti] OR SICCO[ti] OR MAJIC[ti] OR Compare-Acute[ti] OR HAMBRECHT[ti] OR COURAGE[ti] OR "BARI 2D"[ti] OR "FAME 2"[ti] OR DANAMI-3-PRIMULTI[ti] OR OAT[ti] OR DECOP[ti] OR JSAP[ti] OR ISCHEMIA[ti] OR EXACT[ti] OR AWESOME[ti]) |
| | 46 "drug-eluting stents"[tw] |
| | 47 "coronary stent*"[tiab] |
| | 48 "expandable stent*"[tiab] |
| | 49 "**coated stent*"[tiab] |
| | 50 "**eluting stent*"[tiab] |
| | 51 "**encapsulated stent*"[tiab] |
| | 52 "off pump bypass*"[tiab] |
| | 53 "Bare metal stent*"[tiab] |
| | 54 27 OR 28 OR 29 OR 30 OR 31 OR 32 OR 33 OR 34 OR 35 OR 36 OR 37 OR 38 OR 39 OR 40 OR 41 OR 42 OR 43 OR 44 OR 45 OR 46 OR 47 OR 48 OR 49 OR 50 OR 51 OR 52 OR 53 |
| Comparator | 55 "Optimal medical therap*"[tw] |
| | 56 "Optimal medical treatment*"[tw] |
| | 57 "Medical therap*"[tw] |
| | 58 "Medical treatment*"[tw] |
| | 59 OMT[tiab] |
| | 60 "Lipid-lowering therap*"[tiab] |
| | 61 "Anti-ischemic drug*"[tiab] |
| | 62 Statin*[tw] |
| | 63 55 OR 56 OR 57 OR 58 OR 59 OR 60 OR 61 OR 62 |
| Language | 64 English[la] |
| | 65 French[la] |
| | 66 German[la] |
| | 67 Italian[la] |
| | 68 64 OR 65 OR 66 OR 67 |
| Limits | 69 Animals[mh] |
| | 70 Humans[mh] |
| | 71 69 NOT (69 AND 70) |
| | 72 Editorial[pt] |

| Group | Query | |
|------------------------|-------|---|
| | 73 | Letter[pt] |
| | 74 | News[pt] |
| | 75 | Congress[pt] |
| | 76 | 72 OR 73 OR 74 OR 75 |
| Combined search string | 77 | (26 AND 54 AND 63 AND 68) NOT 71 NOT 76 |

Table 5 Search strategy – INAHTA Database

| Group | Query | |
|------------------------|-------|--|
| Population | 1 | “CCS” |
| | 2 | IHD |
| | 3 | “Ischemic heart disease” |
| | 4 | “Ischaemic heart disease” |
| | 5 | “Coronary artery disease” |
| | 6 | Atherosclerosis |
| Intervention | 7 | CABG |
| | 8 | Coronary AND bypass |
| | 9 | PCI |
| | 10 | “Percutaneous coronary intervention” |
| Combined search string | 11 | (1 OR 2 OR 3 OR 4 OR 5 OR 6) AND (7 OR 8 OR 9 OR 10) |

Table 6 Search strategy – International Clinical Trials Registry Platform

| Group | Query |
|-----------------------------|---|
| Population | 1 CCS |
| | 2 chronic coronary syndrome |
| | 3 chronic ischaemic heart disease chronic |
| | 4 chronic ischemic heart disease |
| | 5 stable ischaemic heart disease |
| | 6 stable ischemic heart disease |
| | 7 stable atherosclerosis |
| Intervention | 8 CABG |
| | 9 coronary artery bypass graft |
| | 10 PCI |
| | 11 PTCA |
| | 12 coronary angioplasty |
| | 13 revascularisation |
| | 14 revascularisation |
| Population AND Intervention | 15 (1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7) AND (8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14) |

Table 7 Search strategy – EconLit (EBSCO)

| Group | Query |
|------------------------|---|
| Population | 1 CCS |
| | 2 "coronary artery disease" |
| | 3 "heart disease" |
| | 4 Atherosclerosis |
| | 5 Coronary |
| Intervention | 6 Coronary angioplasty |
| | 7 CABG |
| | 8 Percutaneous coronary intervention |
| | 9 PTCA |
| Combined search string | 10 (1 OR 2 OR 3 OR 4 OR 5) AND (6 OR 7 OR 8 OR 9) |

Table 8 Grey literature sources

| Source | Website |
|---|---|
| American College of Cardiology | www.acc.org |
| Australian Heart Foundation | www.heartfoundation.org.au |
| Austrian Cardiology Society [Österreichische Kardiologie Gesellschaft] | www.atcardio.at |
| Cardiac society of Australia and New Zealand | www.csanz.edu.au |
| European Association for Cardio-Thoracic Surgery | www.eacts.org |
| European Medicines Agency | www.ema.europa.eu |
| European Society of Cardiology | www.escardio.org |
| Federal Statistical Office | www.bfs.admin.ch/bfs/en/home.html |
| French Society of Cardiology [Société Française de Cardiologie] | www.fcadio.fr |
| German Society for Cardiology [Deutsche Gesellschaft für Kardiologie] | www.dgk.org |
| Google | www.google.com |
| The Italian Federation of Cardiology | www.federcardio.it |
| NHS Pathways | www.nhspathways.org |
| National Heart, Lung and Blood Institute | www.nhlbi.nih.gov |
| NPS Medicinewise | www.nps.org.au |
| Swiss Society of Cardiology [Schweizerische Gesellschaft für Kardiologie] | www.swisscardio.ch |
| Trip Database | www.tripdatabase.com |
| World heart federation | www.world-heart-federation.org |
| HTA websites of INAHTA members | |
| Australia | |
| Adelaide Health Technology Assessment (AHTA) | https://www.adelaide.edu.au/ahta/pubs/ |
| Australian Safety and Efficacy Register of New Interventional Procedures—Surgical (ASERNIP-S) | https://www.surgeons.org/research-audit/research-evaluation-inc-asernips |
| Austria | |
| Austrian Institute for Health Technology Assessment (AIHTA) | https://aihta.at/page/homepage/en |
| Gesundheit Österreich GmbH (GOG) | http://www.goeg.at |
| Argentina | |
| Institute for Clinical Effectiveness and Health Policy (IECS) | http://www.iecs.org.ar |
| Belgium | |
| Belgian Health Care Knowledge Centre (KCE) | http://kce.fgov.be |
| Brazil | |
| National Committee for Technology Incorporation (CONITEC) | http://conitec.gov.br/en/ |

| | |
|--|---|
| Agência Nacional de Saúde Suplementar/ National Regulatory Agency for Private Health Insurance and Plans (ANS) | https://www.gov.br/ans/pt-br |
| Canada | |
| Institute of Health Economics (IHE) | http://www.ihe.ca |
| Institut National d'Excellence en Santé et en Services (INESSS) | https://www.inesss.qc.ca/en/home.html |
| The Canadian Agency for Drugs and Technologies in Health (CADTH) | http://www.cadth.ca/ |
| Ontario Health (OH) | https://www.ontariohealth.ca/ |
| Colombia | |
| Instituto de Evaluación Tecnológica en Salud (IETS) | http://www.iets.org.co |
| Denmark | |
| Social & Health Services and Labour Market (DEFAC-TUM) | http://www.defactum.net |
| Finland | |
| Finnish Coordinating Center for Health Technology Assessment (FinCCHTA) | https://www.ppshp.fi/Tutkimus-ja-opetus/FinC-CHTA/Sivut/HTA-julkaisuja.aspx |
| France | |
| French National Authority for Health (Haute Autorité de Santé; HAS) | http://www.has-sante.fr/ |
| Assistance Publique – Hôpitaux de Paris | http://cedit.aphp.fr |
| Germany | |
| Institute for Quality and Efficiency in Health Care (IQWiG) | http://www.iqwig.de |
| Federal Joint Committee (Gemeinsamer Bundesausschuss; G-BA) | https://www.g-ba.de/english/ |
| Ireland | |
| Health Information and Quality Authority (HIQA) | http://www.hiqa.ie |
| Italy | |
| Agenzia Sanitaria e Sociale Regionale (ASSR) | http://www.inahta.org/members/assr/ |
| HTA Unit in A. Gemelli Teaching Hospital (UVT) | https://www.policlinicogemelli.it/ |
| National Agency for Regional Health services (Agenas) | http://www.agenas.it |
| Kazakhstan | |
| Ministry of Public Health of the Republic of Kazakhstan, Republican Centre for Health Development (RCHD) | http://www.rcrz.kz |
| Korea | |
| National Evidence-based healthcare Collaborating Agency (NECA) | www.neca.re.kr/eng |
| Malaysia | |
| Health Technology Assessment Section, Ministry of Health Malaysia (MaHTAS) | http://www.moh.gov.my |
| The Netherlands | |

| | |
|---|---|
| The Netherlands Organisation for Health Research and Development (ZonMw) | http://www.zonmw.nl |
| Zorginstituut Nederland (ZIN) | https://www.zorginstituutnederland.nl/ |
| Norway | |
| The Norwegian Institute of Public Health (NIPHNO) | http://www.fhi.no/ |
| Peru | |
| Institute of Health Technology Assessment and Research (IETSI) | http://www.essalud.gob.pe/ietsi/ |
| Poland | |
| Agency for Health Technology Assessment and Tariff System (AOTMiT) | http://www.aotm.gov.pl |
| Republic of China, Taiwan | |
| Center for Drug Evaluation (CDE) | http://www.cde.org.tw |
| Russian Federation | |
| Center for Healthcare Quality Assessment and Control (CHQAC) | www.rosmedex.ru |
| Singapore | |
| Agency for Care Effectiveness (ACE) | Agency for Care Effectiveness (ACE) (ace-hta.gov.sg) |
| Spain | |
| Agencia de Evaluación de Tecnologías Sanitarias, Instituto de Salud "Carlos III" / Health Technology Assessment Agency (AETS) | http://publicaciones.isciii.es/ |
| Agency for Health Quality and Assessment of Catalonia (AQuAS) | http://aquas.gencat.cat |
| Andalusian HTA Agency | http://www.aetsa.org/ |
| Basque Office for Health Technology Assessment (OSTEBA) | http://www.euskadi.eus/web01-a2ikeost/en/ |
| Galician Agency for Health Technology Assessment (AVALIA-T) | http://acis.sergas.es |
| Health Sciences Institute in Aragon (IACS) | http://www.iacs.es/ |
| Sweden | |
| Swedish Council on Technology Assessment in Health Care (SBU) | http://www.sbu.se/en/ |
| Switzerland | |
| Swiss Federal Office of Public Health (SFOPH) | http://www.bag.admin.ch/hta |
| Tunisia | |
| INEAS – National Authority for Assessment and Accreditation in Healthcare, TUNISIA | http://www.ineas.tn/fr |
| United Kingdom | |
| Healthcare Improvement Scotland (HIS) | http://www.healthcareimprovementscotland.org |
| National Institute for Clinical Excellence (NICE) | http://www.nice.org.uk/ |

| | |
|--|---|
| Health Technology Wales (HTW) | http://www.healthtechnology.wales |
| National Institute for Health Research (NIHR), including HTA programme | http://www.nets.nihr.ac.uk/programmes/hta |
| United States | |
| Agency for Healthcare Research and Quality (AHRQ) | https://www.ahrq.gov/research/findings/index.html |
| Uruguay | |
| Health Assessment Division, Ministry of Public Health (HAD) | http://www.msp.gub.uy |

Abbreviations:

HTA: health technology assessment; **INAHTA:** International Network of Agencies for Health Technology Assessment.